

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



24745

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07K 15/00, C12N 1/20, 9/48 C12N 9/50, 9/52, 9/54 C12N 9/56, 9/58, 9/60 C12N 9/62, 9/64, 9/66 C12N 9/68, 9/70, 9/72 C12N 9/74, 9/76, 15/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 90/10649</p> <p>(43) International Publication Date: 20 September 1990 (20.09.90)</p>
<p>(21) International Application Number: PCT/US90/00947</p> <p>(22) International Filing Date: 1 March 1990 (01.03.90)</p> <p>(30) Priority data: 319,212 6 March 1989 (06.03.89) US 434,748 13 November 1989 (13.11.89) US</p> <p>(71) Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).</p> <p>(72) Inventors: SAMBROOK, Joseph, F. ; 4320 Irvin Simmons Drive, Dallas, TX 75229 (US). MADISON, Edwin, L. ; 6203 Bordeaux Drive, Apt. 202, Dallas, TX 75209 (US). GOLDSMITH, Elizabeth, J. ; 4626 Cherokee Trail, Dallas, TX 75209 (US). GETHING, Maryjane, H. ; 4320 Irvin Simmons Drive, Dallas, TX 75229 (US). GERARD, Robert, D. ; 18620 Featherwood Drive, Dallas, TX 75252 (US).</p>	<p>(74) Agent: KII, Gordon; Sughrus, Mion, Zinn, MacPeak & Seas, 2100 Pennsylvania Avenue, N.W., Suite 800, Washington, DC 20037-3202 (US).</p> <p>(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: SERPIN RESISTANT CHYMOTRYPSIN SUPERFAMILY PROTEASES, PARTICULARLY PAI-1 RESISTANT +-PA, COMPLEMENTARY INHIBITOR MUTANTS; COMPOSITIONS; GENES; EXPRESSION</p> <p>(57) Abstract</p> <p>The present invention relates to serine protease mutants of the chymotrypsin superfamily, particularly +-PA mutants, that are resistant to inhibition by their cognate inhibitors, such as PAI-1 in the case of +-PA, and genes that encode the same. The present invention also relates to serine protease inhibitor mutants, particularly PAI-1 mutants, that inhibit the serine protease mutants of the present invention, particularly +-PA mutants, and genes that encode the same. The serine protease mutants and serine protease inhibitor mutants are useful as, e.g., pharmacological agents.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LJ	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

Serpin Resistant Chymotrypsin SuperFamily Proteases,
Particularly PAI-1 Resistant +-PA, Complementary
Inhibitor Mutants; Compositions; Genes; Expression

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a Continuation-in-part of U.S. Patent Application Serial No. 07/319,212, filed March 6, 1989.

FIELD OF THE INVENTION

The present invention relates to serine protease mutants of the chymotrypsin superfamily that are resistant to inhibition by their cognate inhibitors, and genes that encode the same. The present invention also relates to serine protease inhibitor mutants that inhibit the serine protease mutants of the present invention, and genes that encode the same. The serine protease mutants and serine protease inhibitor mutants are useful as, e.g., pharmacological agents.

BACKGROUND OF THE INVENTION

I. Serine Proteases

Serine proteases (E.C. 3.4.21) are the sub-sub class of endopeptidases that use serine as the nucleophile in peptide bond cleavage (Barrett, A.J., In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 3-22 (1986); and Hartley, B.S., Ann. Rev. Biochem., 29:45-72 (1960)).

Serine proteases are well known in the art and two superfamilies of serine proteases, i.e., the chymotrypsin superfamily and the Streptomyces subtilisin superfamily, have been observed to date (Barrett, A.J., In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 3-22

(1986); and James, M.N.G., In: Proteolysis and Physiological Regulation, Ed. Ribbons, D.W. et al, Academic Press, New York, pages 125-142 (1976)).

Examples of serine proteases of the chymotrypsin superfamily include tissue-type plasminogen activator (hereinafter "t-PA"), trypsin, trypsin-like protease, chymotrypsin, plasmin, elastase, urokinase (or urinary-type plasminogen activator (hereinafter "u-PA")), acrosin, activated protein C, C1 esterase, cathepsin G, chymase and proteases of the blood coagulation cascade including kallikrein, thrombin, and Factors VIIa, IXa, Xa, XIa and XIIa (Barrett, A.J., In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 3-22 (1986); Strassburger, W. et al, FEBS Lett., 157:219-223 (1983); Dayhoff, M.O., Atlas of Protein Sequence and Structure, Vol. 5, National Biomedical Research Foundation, Silver Spring, Maryland (1972); and Rosenberg, R.D. et al, Hosp. Prac., 21:131-137 (1986)).

Some of the serine proteases of the chymotrypsin superfamily, including t-PA, plasmin, u-PA and the proteases of the blood coagulation cascade, are large molecules that contain, in addition to the serine protease catalytic domain, other structural domains responsible in part for regulation of their activity (Barrett, A.J., In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 3-22 (1986); Gerard, R.D. et al, Mol. Biol. Med., 3:449-457 (1986); and Blasi, F. et al, In: Human Genes and Diseases, Ed. Blasi, F., John Wiley & Sons, Ltd., pages 377-414 (1986)).

The catalytic domains of all of the serine proteases of the chymotrypsin superfamily have both sequence homology and structural homology. The sequence homology includes the total conservation of:

- (i) the characteristic active site residues (e.g., Ser₁₉₅, His₅₇ and Asp₁₀₂ in the case of trypsin);
- (ii) the oxyanion hole (e.g., Gly₁₉₃, Asp₁₉₄ in the case of trypsin); and
- (iii) the cysteine residues that form disulfide bridges in the structure (Hartley, B.S., Symp. Soc. Gen. Microbiol., 24:152-182 (1974)).

The structural homology includes:

- (i) the common fold that consists of two Greek key structures (Richardson, J., Adv. Prot. Chem., 34:167-339 (1981));
- (ii) a common disposition of catalytic residues; and
- (iii) detailed preservation of the structure within the core of the molecule (Stroud, R.M., Sci. Am., 231:24-88 (1974)).

A comparison of the sequences of the members of the chymotrypsin superfamily reveals the presence of insertions or deletions of amino acids within the catalytic domains (see for example, Figure 1). In all cases, these insertions or deletions map to the surface of the folded molecule and thus do not effect the basic structure of the molecule (Strassburger, W. et al, FEBS Lett., 157:219-223 (1983)).

II. Serine Protease Inhibitors

Serine protease inhibitors are well known in the art and are divided into the following families:

- (i) the bovine pancreatic trypsin inhibitor (Kunitz) family, also known as basic protease inhibitor (Ketcham, L.K. et al, In: Atlas of Protein Sequence and Structure, Ed. Dayhoff, M.O., pages 131-143 (1978) (hereinafter "BPTI"),
- (ii) the Kazal family,
- (iii) the Streptomyces subtilisin inhibitor family

(hereinafter "SSI"), (iv) the serpin family, (v) the soybean trypsin inhibitor (Kunitz) family, (vi) the potato inhibitor family, and (vii) the Bowman-Birk family (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980); Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986); and Laskowski, M. et al, Cold Spring Harbor Symp. Quant. Biol., LII:545-553 (1987)).

Crystallographic data are available for a number of intact inhibitors including members of the BPTI, Kazal, SSI, soybean trypsin and potato inhibitor families, and for a cleaved form of the serpin alpha-1-antitrypsin (Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986)). Despite the fact that these serine protease inhibitors are proteins of diverse size and sequence, the intact inhibitors studied to date all have in common a characteristic loop extending from the surface of the molecule that contains the recognition sequence for the active site of the cognate serine protease (Levin, E.G. et al, Proc. Natl. Acad. Sci. USA, 80:6804-6808 (1983)). The structural similarity of the loops in the different serine protease inhibitors is remarkable (Papamokos, E. et al, J. Mol. Biol., 158:515-537 (1982)). Outside of the active site loop, the serine protease inhibitors of different families are generally unrelated structurally, although the Kazal family and Streptomyces subtilisin family of inhibitors display some structural and sequence similarity.

Many of the serine protease inhibitors have a broad specificity and are able to inhibit both the chymotrypsin superfamily of proteases, including the blood coagulation serine proteases, and the

Streptomyces subtilisin superfamily of serine proteases (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)). The specificity of each inhibitor is thought to be determined primarily by the identity of the amino acid that is immediately amino-terminal to the site of potential cleavage of the inhibitor by the serine protease. This amino acid, known as the P₁ site residue, is thought to form an acyl bond with the serine in the active site of the serine protease (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)).

A. The BPTI Family

Serine protease inhibitors belonging to the BPTI family include BPTI, snake venom inhibitor, inter-alpha inhibitor, and the A4 amyloid precursor A4695 (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980); Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986); and Ponte, P. et al, Nature, 331:525-527 (1988)). Examples of serine proteases and their cognate BPTI family inhibitors are listed in Table I below.

Table I

<u>Serine Protease</u>	<u>Cognate BPTI Inhibitor</u>
Trypsin	BPTI Snake venom inhibitor Inter-alpha inhibitor
(Unknown)	A4 amyloid precursor A4695 protease nexin II

B. The Kazal Family

Serine protease inhibitors belonging to the Kazal family include pancreatic secretory inhibitor, ovomucoid and seminal plasma acrosin inhibitor

(Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980); Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986); and Laskowski, M. et al, Cold Spring Harbor Symp. Quant. Biol., LII:545-553 (1987)). Examples of serine proteases and their cognate Kazal family inhibitors are listed in Table II below.

Table II

<u>Serine Protease</u>	<u>Cognate Kazal Inhibitor</u>
Trypsin	Pancreatic secretory inhibitor Ovomucoid Seminal plasma acrosin inhibitor
Acrosin	Ovomucoid Seminal plasma acrosin inhibitor

C. The Streptomyces Subtilisin Inhibitor

Serine protease inhibitors belonging to the Streptomyces subtilisin inhibitor family include inhibitors obtained from Streptomyces albobriseolus and plasminostreptin (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)). Examples of serine proteases and their cognate Streptomyces subtilisin class inhibitors are listed in Table III below.

Table III

<u>Serine Protease</u>	<u>Cognate SSI Inhibitor</u>
Subtilisin BPN'	<u>Streptomyces albobriseolus</u> inhibitor
Plasmin	Plasminostreptin
Trypsin	Plasminostreptin

D. The Serpin Family

Serine protease inhibitors belonging to the serpin family include the plasminogen activator inhibitors PAI-1, PAI-2 and PAI-3, C1 esterase inhibitor, alpha-2-antiplasmin, contrapsin, alpha-1-antitrypsin, antithrombin III, protease

nexin I, alpha-1-antichymotrypsin, protein C inhibitor, heparin cofactor II and growth hormone regulated protein (Carrell, R.W. et al, Cold Spring Harbor Symp. Quant. Biol., 52:527-535 (1987); Sommer, J. et al, Biochem., 26:6407-6410 (1987); Suzuki, K. et al, J. Biol. Chem., 262:611-616 (1987); and Stump, D.C. et al, J. Biol. Chem., 261:12759-12766 (1986)).

The inhibition of serine proteases by serpins has been reviewed in Travis, J. et al, Ann. Rev. Biochem., 52:655-709 (1983); Carrell, R.W. et al, Trends Biochem. Sci., 10:20-24 (1985); Sprengers, E.D. et al, Blood, 69:381-387 (1987); and Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam (1986).

Examples of serine proteases and their cognate serpin inhibitors are listed in Table IV below.

Table IV

<u>Serine protease</u>	<u>Cognate Serpin Inhibitor</u>
Activated protein C	Protein C inhibitor PAI-1
Cl esterase	Cl esterase inhibitor
Cathepsin G	Alpha-1-antitrypsin Alpha-1-antichymotrypsin
Chymase	Alpha-1-antichymotrypsin
Chymotrypsin	Alpha-1-antichymotrypsin Alpha-2-antiplasmin Contrapsin
Coagulation factors (VIIa, IXa, Xa, XIa, XIIa)	Antithrombin III Cl esterase inhibitor
Elastase	Alpha-1-antitrypsin
Kallikrein	Cl esterase inhibitor Alpha-1-antitrypsin
Plasmin	Alpha-2-antiplasmin
Thrombin	Antithrombin III Heparin cofactor II
t-PA	PAI-1, PAI-2, PAI-3
Trypsin	Alpha-1-antitrypsin Growth hormone regulated protein
Trypsin-like protease	Protease nexin I
u-PA	PAI-1, PAI-2, PAI-3

E. The Soybean Trypsin Inhibitor Family

A single example of the soybean trypsin inhibitor family, purified from soybeans, has been sequenced. Its complex with bovine pancreatic trypsin has been studied (Sweet, R.M. et al, Biochem., 13:4214-4228 (1974)).

F. The Potato Inhibitor Family

Serine protease inhibitors belonging to the potato inhibitor family include inhibitors from potatoes, barley and leeches (Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986)). Examples

of serine proteases and their potato inhibitors are listed in Table V below.

Table V

<u>Serine Protease</u>	<u>Potato Inhibitor</u>
Chymotrypsin	Barley chymotrypsin inhibitor
<u>Subtilisin</u> Novo	Barley chymotrypsin inhibitor
<u>Subtilisin</u> Carlsberg	Leech inhibitor eglin

G. The Bowman-Birk Inhibitor Family

Serine protease inhibitors belonging to the Bowman-Birk inhibitor family include homologous proteins from legumes (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)). Examples of serine proteases and their Bowman-Birk inhibitors are listed in Table VI below.

Table VI

<u>Serine Protease</u>	<u>Bowman-Birk Inhibitor</u>
Trypsin	Lima bean inhibitor IV
Elastase	Garden bean inhibitor
Chymotrypsin	Adzuki bean inhibitor II

III. Serine Protease-Inhibitor Complexes

Serine protease inhibitors of all families form stable 1:1 complexes with their cognate serine proteases. These complexes dissociate only slowly (hours to days) (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980); and Levin, E.G., Proc. Natl. Acad. Sci. USA, 80:6804-6808 (1983)). For all serine protease inhibitors, except the serpins, the dissociation products are a mixture of the intact and cleaved inhibitor molecules. On the other hand, since dissociation of serine protease-serpin complexes appears to yield only cleaved inhibitor molecules, serpins are thought to utilize a mechanism

somewhat distinct from that of the other serine protease inhibitors.

Structural data are available for several serine protease-inhibitor complexes, including trypsin-BPTI, chymotrypsin-ovomucoid inhibitor, chymotrypsin-potato inhibitor, and Streptomyces subtilisin-Streptomyces subtilisin inhibitor (Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986)). Examination of these structures reveals remarkable similarities in the specific interactions between each inhibitor and its cognate serine protease, despite the diverse sequences of the inhibitors. This structural similarity has suggested in the present invention that even when crystal structures are not available, it may be possible to predict the amino acid interactions occurring between an inhibitor and its cognate serine protease.

As discussed above, the inhibitors contain a reactive center that serves as a competitive substrate for the active site of the serine protease. Attack on the peptide bond between the P_1 - P_1' residues of the reactive center (e.g., Arg₃₄₆-Met₃₄₇ in the case of PAI-1) does not lead to the normal, rapid dissociation of the products from the serine protease but, rather, to the establishment of a stable serine protease-inhibitor complex, probably by formation of a covalent bond between the serine of the active site of the protease and the P_1 residue of the inhibitor (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)). This mechanism indicates that the reactive center of an inhibitor, such as PAI-1, must fit tightly and precisely into the active site of the serine protease. However, to date, there are no X-ray crystallographic data on PAI-1, its cognate serine protease, t-PA, or the

t-PA/PAI-1 complex. Thus, the exact nature of the interactions between this pair of proteins is unknown. There is a similar lack of structural information about other serpins or serpin-serine protease complexes.

IV. Utility of Serine Proteases

A particularly important serine protease of the chymotrypsin superfamily is t-PA. t-PA is currently being used, via intracoronary or intravenous administration, to treat myocardial infarction, pulmonary embolism, and deep venous thrombosis, although it does not work directly to dissolve thrombi (blood clots). Rather, t-PA promotes cleavage of the peptide bond between Arg₅₆₀ and Val₅₆₁ of plasminogen (Robbins, K.C. et al, J. Biol. Chem., 242:2333-2342 (1967)), thereby converting the inactive zymogen into the powerful but non-specific protease, plasmin, which then degrades the fibrin mesh work of the blood clot (Bachmann, F. et al, Semin. Throm. Haemost., 43:77-89 (1984); Gerard, R.D. et al, Mol. Biol. Med., 3:449-557 (1986); and Verstraete, M. et al, Blood, 67:1529-1541 (1986)).

t-PA produces local fibrinolysis without necessarily depleting systemic fibrinogen. This is because t-PA has the ability to bind directly to fibrin, forming a fibrin-t-PA complex whose affinity for plasminogen is increased approximately 500 fold (Ranby, M. et al, Biochim. Biophys. Acta, 704:461-469 (1982); and Rijken, D.C. et al, J. Biol. Chem., 257:2920-2925 (1982)). Thus, binding of intravenously-administered t-PA to coronary thrombi, where plasminogen is also present in high concentration (Wiman, B. et al, Nature, 272:549-550 (1978)), results in efficient production of plasmin

at the site of the thrombus where it will do the most good.

At present, t-PA is administered in the form of an initial bolus that is followed by sustained infusion. The total amount of enzyme administered during a standard 3 hour treatment is generally about 50-100 mg. Such large amounts are apparently required for two reasons: first, to counterbalance the effects of rapid clearance of t-PA from the circulation by hepatic cells (Krause, J., Fibrinolysis, 2:133-142 (1988)), and second, to overcome the effects of comparatively high concentrations of serine protease inhibitors that are present in plasma and platelets (Carrell, R.W. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 403-420 (1986)).

The major physiological inhibitor of t-PA is the serpin, PAI-1, a glycoprotein of approximately 50 kd (Pannekoek, H. et al, EMBO J., 5:2539-2544 (1986); Ginsberg, D. et al, J. Clin. Invest., 78:1673-1680 (1980); and Carrell, R.W. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 403-420 (1986)). PAI-1 has been implicated as the cause of reduced fibrinolytic capacity of plasma from survivors of myocardial infarctions (Hamsten, A. et al, New Eng. J. Med., 313:1557-1563 (1985)). In addition, PAI-1 is an acute phase reactant and the elevated levels associated with myocardial infarction may attenuate the fibrinolytic activity of substantial amounts of the t-PA remaining in the plasma after therapeutic infusion of the t-PA (Lucore, C.L. et al, Circ., 77:660-669 (1988)). The second-order rate constant for association of PAI-1 with t-PA is extremely high (Hekman, C. et al, Arch. Biochem. Biophys., 262:199-210 (1988)) and accounts for the initial,

"fast-phase" inhibition of t-PA by human plasma (Colucci, M. et al, J. Lab. Clin. Med., 108:53-59 (1986)). The rapid neutralization of t-PA by PAI-1 in vivo, may therefore contribute to coronary restenosis after thrombolytic therapy, a complication that affects between 10% and 35% of patients treated for acute myocardial infarction (Chesebro, J.H. et al, Circ., 76:142-154 (1987)).

Although the association constants of other serpins, such as C1 esterase inhibitor and alpha-2-antiplasmin, with t-PA are orders of magnitude lower than that of PAI-1 (Ranby, M. et al, Throm. Res., 27:175-183 (1982); and Hekman, C. et al, Arch. Biochem. Biophys., 262:199-210 (1988)), these serpins nevertheless bind to infused t-PA (Lucore, C.L. et al, Circ., 77:660-669 (1988)) and may attenuate the beneficial pharmacological properties of t-PA.

Besides t-PA and PAI-1, many other serine protease-serpin pairs are of great medical importance. For example u-PA, like t-PA, is useful in the treatment of myocardial infarction and is subject to inhibition by the same serine protease inhibitors as t-PA.

Thrombin, the serine protease used topically to promote blood clotting of wounds, is a procoagulant. Its cognate serpin, antithrombin III, is an anti-coagulant that specifically inhibits a number of serine proteases that participate in the blood coagulation cascade, including thrombin and Factors IXa, Xa, XIa and XIIa (Heimburger, N. et al, In: Proceedings of the International Research Conference on Proteinase Inhibitors, Ed. Fritz, H. et al, Walter de Gruyter, New York, pages 1-22 (1971); Kurachi, K. et al, Biochem., 15:373-377 (1976); Kurachi, K. et al, Biochem., 16:5831-5839 (1977); and Osterud, B. et

al, Semin. Thromb. Haemost., 35:295-305 (1976)). Antithrombin III has been used therapeutically to treat disseminated intravascular coagulation. The activation of protein C by thrombin results in the self-limitation of the blood coagulation process because activated protein C inactivates coagulation factors Va and VIIIa, and is itself inhibited by its cognate serpin, protein C inhibitor.

Kallikrein, which functions to induce uterine contraction, to increase vascular permeability, and to initiate the intrinsic pathway of blood coagulation, is subject to inhibition by the serpin alpha-1-antitrypsin, one of the more important serpins.

Alpha-1-antitrypsin also inhibits leukocyte elastase and cathepsin, as well as trypsin, chymotrypsin and plasmin (Heimburger, N. et al, In: Proceedings of the International Research Conference on Proteinase Inhibitors, Ed. Fritz, H. et al, Walter de Gruyter, New York, pages 1-47 (1971); Janoff, A., Am. Rev. Resp. Dis., 105:121-127 (1972); and Ohlsson, K. et al, Eur. J. Biochem., 36:473-481 (1973)). The genetic deficiency of alpha-1-antitrypsin is directly related to emphysema (Carrell, R.W. et al, Trends Biochem. Sci., 10:20-24 (1985)) and alpha-1-antitrypsin replacement therapy has been used to treat emphysema (Marx, J.L., Science, 243:315-316 (1989)).

SUMMARY OF THE INVENTION

Accordingly, an object of the present invention is to improve wild-type serine proteases of the chymotrypsin superfamily, and in particular wild-type t-PA, by protein engineering, so as to increase their enzymatic efficiency and/or to alter the dosage

thereof required without necessarily altering other beneficial pharmacological properties.

Another object of the present invention is to provide genes encoding the improved serine proteases of the chymotrypsin superfamily.

Still another object of the present invention is to alter wild-type serine protease inhibitors, particularly those of the serpin family, and in particular, wild-type PAI-1, so as to increase their inhibitory efficiency and/or to alter the dosage thereof required and render them capable of inhibiting the mutant serine proteases of the present invention.

Yet another object of the present invention is to provide genes encoding the improved serine protease inhibitors.

These and other objects of the present invention, which will be apparent from the detailed description of the present invention provided hereinafter, have been met by serine protease mutants of the chymotrypsin superfamily which are resistant to inhibition by their cognate inhibitors; and genes encoding the same; and by serine protease inhibitor mutants that inhibit the serine protease inhibitor-resistant serine proteases; and genes encoding the same.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a comparison of the sequences of various serine proteases of the chymotrypsin superfamily. The sequences are aligned so as to demonstrate overlap of conserved amino acids. The numbers above trypsin refer to the numbering system used in the PDB3ptp.ent entry in the Protein Data Bank. The numbers above t-PA refer to the amino acids in the mature t-PA molecule.

Figure 2 shows a comparison of the sequences of various members of the serpin family of serine protease inhibitors. The sequences are aligned so as to demonstrate overlap of conserved amino acids. The numbers below alpha-1-antitrypsin and the numbers above PAI-1 refer to amino acid residues in the mature molecules.

Figure 3 schematically illustrates the construction of the vectors employed to mutate and express the wild-type t-PA and the serpin-resistant mutants of t-PA of the present invention.

Figure 4 shows a comparison of the activities of wild-type t-PA and serpin-resistant mutants of t-PA in an indirect chromogenic assay. In Figure 4, \bullet represents wild-type t-PA, \circ represents t-PA(R₃₀₄->S), \square represents t-PA(R₃₀₄->E), and \cdot represents t-PA(Del₂₉₆₋₃₀₂).

Figure 5 shows the effect of PAI-1 on the activities of wild-type t-PA and serpin-resistant mutants of t-PA in an indirect chromogenic assay. In Figure 5, \bullet represents wild-type t-PA, \circ represents t-PA(R₃₀₄->S), \square represents t-PA(R₃₀₄->E), and \cdot represents t-PA(Del₂₉₆₋₃₀₂).

Figure 6 shows a comparison of the activities of wild-type t-PA and serpin-resistant mutants of t-PA in an indirect chromogenic assay. In Figure 6, \square represents t-PA(H₂₉₇->Y), \cdot represents wild-type t-PA, $+$ represents t-PA(K₂₉₆->E), \bullet represents the triple mutant t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E), \blacktriangle represents t-PA(R₂₉₉->E), \triangle represents t-PA(R₂₉₈->E) and \circ represents t-PA(P₃₀₁->G).

Figure 7 shows the effect of PAI-1 on the activities of wild-type t-PA and serpin-resistant mutants of t-PA in an indirect chromogenic assay. In Figure 7, \square represents t-PA(H₂₉₇->Y), \cdot represents wild-type t-PA, $+$ represents t-PA(K₂₉₆->E),

• represents t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E),
▲ represents t-PA(R₂₉₉->E), △ represents
t-PA(R₂₉₈->E) and o represents t-PA(P₃₀₁->G).

Figure 8 schematically illustrates the construction of the vectors employed to mutagenize and express the wild-type PAI-1 and the mutants of PAI-1 of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

As discussed above, the above-described objects of the present invention have been met in one embodiment by serine protease mutants of the chymotrypsin superfamily that are resistant to inhibition by their cognate inhibitor; and genes encoding the same.

In another embodiment of the present invention, the above-described objects have been met by serine protease inhibitor mutants that inhibit the serine protease inhibitor-resistant serine proteases of the present invention; and genes encoding the same.

In still another embodiment, the serine protease inhibitor mutants of the present invention also inhibit the wild-type serine protease of the chymotrypsin superfamily.

The particular serine protease of the chymotrypsin superfamily employed in the present invention is not critical thereto as all members of this serine protease sub-sub class of endopeptidases are homologous proteins that share a common mechanism of action. Specific examples of such serine proteases of the chymotrypsin superfamily include those listed above, i.e., t-PA, trypsin, trypsin-like protease, chymotrypsin, plasmin, elastase, u-PA, acrosin, activated protein C, C1 esterase, cathepsin G, chymase and proteases of the blood coagulation cascade including kallikrein, thrombin,

and Factors VIIa, IXa, Xa, XIa and XIIa. The preferred serine protease of the chymotrypsin superfamily employed in the present invention is t-PA.

The particular serine protease inhibitor to which the mutant serine protease of the chymotrypsin superfamily is resistant to inhibition, is not critical to the present invention. Examples of such inhibitors include members of the BPTI family, the Kazal family, the SSI family, the serpin family, the soybean trypsin inhibitor (Kunitz) family, the potato inhibitor family, and the Bowman-Birk family.

The particular BPTI inhibitor to which the mutant serine protease of the chymotrypsin superfamily is resistant to inhibition, is not critical to the present invention. Examples of such BPTI inhibitors include BPTI, snake venom inhibitor, inter-alpha inhibitor, and the A4 amyloid precursor A4695.

The particular Kazal inhibitor to which the mutant serine protease of the chymotrypsin superfamily is resistant to inhibition, is not critical to the present invention. Examples of such Kazal inhibitors include pancreatic secretory inhibitor, ovomucoid and seminal plasma acrosin inhibitor.

The particular serpin inhibitor to which the mutant serine protease of the chymotrypsin superfamily is resistant to inhibition, is not critical to the present invention. Examples of such serpin inhibitors include PAI-1, PAI-2, PAI-3, C1 esterase inhibitor (C1inh), protein C inhibitor (PCinh), heparin cofactor II (HCII), alpha-2-antiplasmin (A2AP), antithrombin III (ATIII), alpha-1-antitrypsin (A1AT), protease nexin I (Nex-1), contrapsin (Cntrps), growth hormone

regulated protein (GHRP), and alpha-1-antichymotrypsin (AChym). The preferred serpin, to which the serine protease of the chymotrypsin superfamily is resistant to inhibition, is PAI-1.

The particular serine protease inhibitor, from which the mutant serine protease inhibitor capable of inhibiting the serine protease inhibitor-resistant serine proteases of the chymotrypsin superfamily of the present invention is derived, is not critical to the present invention. Examples of such serine protease inhibitors include members of the BPTI, Kazal, SSI, Kunitz, potato inhibitors, Bowman-Birk and serpin families, preferably serine protease inhibitors of the serpin family such as PAI-1, PAI-2, PAI-3, C1 esterase inhibitor, protein C inhibitor, heparin cofactor II, alpha-2-antiplasmin, antithrombin III, alpha-1-antitrypsin, protease nexin I, contrapsin, growth hormone regulated protein, and alpha-1-antichymotrypsin. The preferred mutant serpin that will inhibit the serine protease inhibitor-resistant serine proteases of the chymotrypsin superfamily is PAI-1.

All known serine protease inhibitors are structurally homologous in their reactive center loop and form similar interactions with their cognate serine proteases (Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986)). The structural correspondences between serine proteases and serine protease inhibitors can be used to build models of complexes that have not been studied heretofor.

Because of the high degree of structural homology between the catalytic domain of t-PA and other serine proteases (Blundell, T. et al, Nature, 326:347-352 (1987)), it was postulated in the present

invention that the known structure of the complex between trypsin and BPTI (Huber, R. et al, J. Mol. Biol., 89:73-101 (1974)); and Bode, W. et al, In: Proteolysis and Physiological Regulation, Academic Press, New York, pages 43-76 (1976)) might serve as a model for the interaction between t-PA and PAI-1. Other than the amino acids in the major recognition site, the amino acids of trypsin that make direct contact with BPTI are located in two separate regions of the polypeptide chain (residues 37-41 and 210-213) (see Figure 1).

The region around amino acid residues ²¹⁴SWGS₂₁₇ is highly conserved among all members of the chymotrypsin superfamily. By contrast, the region around amino acid residues ³⁶NSGYHF₄₁ is more variable and forms part of the surface that interacts with the inhibitor. As shown in Figure 1, the amino acid sequence of t-PA in this region differs from that of trypsin in two major respects. First, the Tyr (Y₃₉) residue of trypsin has been replaced with an Arg (R₃₀₄) residue in t-PA. Modelling based on the assumption that the interaction between t-PA and PAI-1 mimics that between trypsin and BPTI suggests that R₃₀₄ of t-PA can form a salt bridge with a Glu (E₃₅₀) residue of PAI-1. This Glu residue in PAI-1 is equivalent in position to I₁₉ of BPTI (Table VII below) which forms a van der Waal's contact with Y₃₉ of trypsin (Huber, R. et al, J. Mol. Biol., 89:73-101 (1974)); and Bode, W. et al, In: Proteolysis and Physiological Regulation, Academic Press, New York, pages 43-76 (1976)). Therefore, E₃₅₀ of PAI-1 is predicted to form an ion pair with R₃₀₄ of t-PA.

Table VII

	P1	P4'
BPTI	12	24
	GPCXARIIRYFYN	
PAI-1	343	355
	VSARMAPEEIIMD	
PLG	557	569
	CPCRVTGGCVAMP	

Second, t-PA carries an additional stretch of seven amino acids (₂₉₆KHRRSPG₃₀₂, see Figure 1) located adjacent to predicted contact between t-PA(R₃₀₄) and PAI-1(E₃₅₀). Four out of seven of these amino acids are positively-charged, while the predicted complementary region of PAI-1(₃₅₀EEIIMD₃₅₅) contains three negatively-charged residues. It was believed in the present invention that electrostatic interactions between these regions may play an important role in the formation or stabilization of complexes between t-PA and PAI-1. By contrast, such interactions could not occur when t-PA interacts with its substrate, plasminogen (PLG), which has no negatively-charged residues in the equivalent region (see Table VII above).

Comparisons of sequences of various serine proteases of the chymotrypsin superfamily, such as those shown in Figure 1, can be used as a guide to design one or more mutations in the various serine proteases of the chymotrypsin superfamily so as to make them resistant to inhibition by their cognate wild-type inhibitors. Like t-PA, the other serine proteases of the chymotrypsin superfamily shown in Figure 1 differ from trypsin at the important contact residue (Y₃₉ of trypsin) and in containing insertions of variable size located adjacent to the contact residue. Thus, examples of candidates for mutation include:

- (i) amino acid residues that, in other serine proteases, occupy the position equivalent to that of Tyr (Y_{39}) of trypsin (the residue that forms a contact with Ile (I_{19}) of BPTI and therefore plays an important role in the interaction between the two proteins). In plasmin for example, a Met (M) residue occupies the position equivalent to Y_{39} of trypsin. Mutation of this Met residue to another amino acid with different properties, such as charge or size (Glu (E) for example) is expected to eliminate or reduce the susceptibility of plasmin to inactivation by antiplasmin, although the particular substitute amino acid employed is not critical to the present invention. Similarly, mutation of the Gln (Q) residue of thrombin (that occupies the position equivalent to Y_{39} of trypsin) to another amino acid with different properties, such as charge or size (for example Asp (D)) is expected to eliminate or reduce the susceptibility of thrombin to inactivation by antithrombin III, although the particular substitute amino acid employed is not critical to the present invention; and
- (ii) residues of other serine proteases of the chymotrypsin superfamily that are not present in trypsin and map near the active site as small insertions on the surface of the molecule (see Figure 1). For example plasmin contains an insert of 2 amino acids (RF) adjacent to the contact residue in a position equivalent to that occupied by $^{296}\text{KHRRSPG}_{302}$ of t-PA. Mutation by

deletion or substitution of either or both of these two amino acids, or by insertion of small numbers of additional amino acids is expected to eliminate or reduce the interaction with the inhibitor without necessarily affecting the catalytic site of the serine protease. As another example, u-PA contains an insert of six amino acids (RHRGGS) adjacent to the contact residue in a position equivalent to that occupied by $^{296}\text{KHRRSPG}_{302}$ of t-PA. Mutation or deletion of these six residues is expected to reduce or eliminate the interaction with serine protease inhibitors in a manner similar to that observed for the mutant t-PA(Del $_{296-302}$).

Similarly, the region of the serine protease inhibitors within the reactive center is quite variable and forms part of the surface that interacts with the serine protease. Comparisons of sequences of various serine protease inhibitors of the serpin family, such as those shown in Figure 2, can be used as a guide to design one or more mutations in the various serine protease inhibitors, and in particular, in members of the serpin family of serine protease inhibitors, so as to make them able to efficiently inhibit the serine protease inhibitor-resistant serine proteases of the chymotrypsin superfamily of the present invention. Like PAI-1, other serpin family members shown in Figure 2 differ in sequence in the important contact amino acid residues (E_{350} of PAI-1) and contain insertions of variable size located adjacent to the contact residue (see Table VIII below).

Table VIIISerpin

	344	P1-P1'	358
h PAI-1	S A - R M A P E E - - - -	I I M D R P F	
r PAI-1	S A - R M A P T E - - - -	M V L D R S F	
h PAI-2	T G - R T G H G G - - -	P Q F V A D H P F	
h A1AT	I P - M S I P P E - - - -	V K F N K P F	
b A1AT	I P - M S I P P E - - - -	V K F N K P F	
m A1AT	V P - Y S M P P I - - - -	L R F D H P F	
r GHRP	L - - K S L P Q T I - -	P L L N F N R P F	
h AChym	T L - L S A L V E T R T I -	V R F N R P F	
m Cntrps	G I R K A I L P A - - - -	V H F N R P F	
h ATIII	A G - R S L N P N - -	R V T F K A N R P F	
h HCII	M P - L S T Q V R - - - -	F T V D R P F	
h A2AP	S - - R M S L S S - - - -	F S V N R P F	
h Clinh	A A - R T L L V - - - -	F E V Q Q P F	
h PCinh	T F - R S A R L N - -	S Q R L V F N R P F	
r Nex-1	A - - R S S P P W - - - -	F I V D R P F	

(h=human; r=rat; b=baboon; and m=mouse)

Thus, examples of candidates for mutation include:

- (i) amino acid residues that, in other serine protease inhibitors, occupy the position (P4') equivalent to that of Glu(E₃₅₀) of PAI-1 (the residue that forms a contact with Arg(R₃₀₄) of t-PA and therefore plays an important role in the interaction of the two proteins). In the present invention, the Glu residue of PAI-1(E₃₅₀) has been mutated to Arg (R) in order to restore the electrostatic interaction which was disrupted by construction of the R₃₀₄->E mutation in t-PA. This specific mutation in the serpin

has been constructed so as to be complementary to the mutation that was introduced in the serine protease which renders it resistant to inhibition by the wild-type serpin. This complementary E₃₅₀->R mutation in the serpin was specifically chosen to render the serpin capable of inhibiting the serine protease inhibitor-resistant serine proteases of the chymotrypsin superfamily of the present invention; however, the particular substitute amino acid employed is not critical to the present invention. For example, if the Met (M) residue in plasmin equivalent to Y₃₉ of trypsin (see Figure 1) were altered to another amino acid with different properties, such as charge or size (as the example given above, Glu (E)), and that mutant plasmin showed reduced susceptibility to inhibition by wild-type alpha-2-antiplasmin, then mutation of the P4' Ser (S) residue in alpha 2-antiplasmin, to another amino acid (Arg (R) for example) capable of interacting with the altered Glu residue in plasmin, is expected to restore the susceptibility of the mutant plasmin to inactivation by the mutant alpha-2-antiplasmin. Similarly, if the Gln (Q) residue of thrombin were altered to Asp (D), as in the example for mutation of thrombin given above, then mutation of the P6' Arg (R) residue of antithrombin III to Glu (E) is expected to restore susceptibility of the wild-type inhibitor-resistant thrombin to inhibition by the mutant anti-thrombin III; and

- (ii) additional amino acid residues of other members of the various families of serine protease inhibitors within the reactive center that form part of the interaction surface with their cognate serine protease. These residues are shown in Table VIII above for the serpin family of serine protease inhibitors.

For example, alpha-2-antiplasmin contains the sequence SLSSFSVN in the reactive center in a position equivalent to the ³⁴⁸APEEIIMD₃₅₅ of PAI-1. Mutation by substitution of any of these eight amino acids or by insertion of small numbers of additional amino acids is expected to restore the interaction with the serine protease provided that those substitutions or insertions are complementary in some property, such as charge or size or hydrophobicity, to the amino acid residues that were introduced into the serine protease, which originally rendered it resistant to the wild-type serpin.

The mutant serine proteases and mutant serine protease inhibitors of the present invention may be point mutants, deletion mutants, addition mutants, or mutants containing combinations of these types of mutations.

The mutant serine proteases and mutant serine protease inhibitors of the present invention can be prepared, e.g., by the well known techniques of oligonucleotide-mediated mutagenesis (Zoller, M. et al, DNA, 3:479-488 (1984); Kunkel, T. et al, Proc. Natl. Acad. Sci. USA, 82:488- 492 (1985); and Kunkel, T. et al, Current Protocols in Molecular Biology, Green Publishing Associates & Wiley Interscience, New York (1987)). However, the precise method of preparing the mutation in the serine protease or

serine protease inhibitor is not critical to the present invention.

The mutant serine proteases of the present invention can be screened for those having the desired properties, i.e., serine protease activity yet resistance to inhibition by the cognate inhibitor, using well known assays, such as described in Lottenberg, R. et al, Meth. Enzymol., 80:341-361 (1981).

The mutant serine protease inhibitors of the present invention can be screened for those having the desired properties, i.e., serine protease inhibitor activity against the serine protease inhibitor-resistant serine proteases of the present invention, using well-known assays, such as described in Lottenberg, R. et al, Meth. Enzymol., 80:341-361 (1981); Holmes, W.E. et al, Biochem., 26:5133-5140 (1987); and Hekman, C.M. et al, Arch. Biochem. Biophys., 262:199-210 (1988).

The work described herein demonstrates for the first time that it is possible to modify serine proteases by mutagenesis so as to reduce or eliminate the interaction between serine proteases of the chymotrypsin superfamily and their cognate inhibitors. This allows the mutant serine proteases to remain enzymatically more active than the wild-type enzyme in the presence of the cognate inhibitors, with the amount of residual activity depending on the degree to which their interaction with their cognate inhibitor is inhibited. The administration of such mutated serine proteases is believed to be of benefit in a variety of clinical and commercial applications. For example, a mutated form of activated protein C is believed to be useful when it would be advantageous to inhibit the coagulation of blood, just as the mutated forms of

t-PA described in Example 1 herein are believed to be useful to extend the effective life of t-PA in the circulation of a patient with a thrombotic disorder where extended fibrinolysis is required.

The work described herein also demonstrates for the first time that it is possible to modify serine protease inhibitors by mutagenesis so as to functionally restore the interaction between serine protease inhibitor-resistant mutant serine proteases of the chymotrypsin superfamily and their cognate serine protease inhibitors by suitably altering the structure of the serine protease inhibitor. This allows the mutant serine proteases to be inactivated more rapidly than they would be in the presence of the cognate wild-type serine protease inhibitor, with the rate of inhibition depending on the degree to which their interaction with the mutant serine protease has been restored. The administration of such mutant serine protease inhibitors is believed to be of benefit in a variety of clinical and commercial applications to limit the activity of serine protease inhibitor-resistant serine proteases. For example, a mutated form of protein C inhibitor is believed to be useful where it would be advantageous to promote the coagulation of blood in the presence of a mutant form of activated protein C. Similarly, the mutated forms of PAI-1 are believed to be useful in shortening the effective life of serine protease inhibitor-resistant t-PA, e.g. t-PA(R₃₀₄->E), in the circulation of a patient treated for a thrombotic disorder should an invasive procedure be required. Such altered serine protease inhibitors could thus be used as antidotes for the serine protease inhibitor-resistant serine proteases.

The amount of mutant serine protease of the present invention to be administered in clinical

applications will depend upon the particular mutant serine protease employed, the desired therapeutic effect of the serine protease, and on factors such as the sex, age, weight and physiological condition of the patient to whom the protease is to be administered. The amount of mutant serine protease to employ can be determined by routine experimentation.

The amount of mutant serine protease inhibitor of the present invention to be administered in clinical applications will depend upon the particular mutant serine protease inhibitor employed, the desired therapeutic effect of the serine protease inhibitor, and on factors such as the sex, age, weight and physiological condition of the patient to whom the serine protease inhibitor is to be administered. The amount of mutant serine protease inhibitor to employ can be determined by routine experimentation.

The mutant t-PAs of the present invention should be administered as determined by tests in appropriate in vitro and in vivo models and in clinical trials. It is anticipated that the doses required will be between 10 and 1000-fold less than that which is required for wild-type t-PA.

The mutant PAI-1s of the present invention should also be administered as determined by tests in appropriate in vitro and in vivo models and in clinical trials. It is anticipated that the doses required will be approximately the same as those required for the mutant t-PAs.

The mutant serine proteases of the present invention can be administered with any pharmaceutically acceptable carrier or diluent as is well known in the art, such as a physiological saline solution (Lucore, C.L. et al, Circ., 77:660-669

(1988); and Chesebro, J.H. et al, Circ., 76:142-154 (1987)).

The mutant serine protease inhibitors of the present invention can also be administered with any pharmaceutically acceptable carrier or diluent as is well known in the art, such as a physiological saline solution (Lucore, C.L. et al, Circ., 77:660-669 (1988); and Chesebro, J.H. et al, Circ., 76:142-154 (1987)).

The particular mode of administration of the mutant serine proteases of the present invention is dependent on the particular application thereof. Examples of such modes of administration include intravenous or intraperitoneal injection, intracoronary infusion, topical application and aerosol inhalation.

The particular mode of administration of the mutant serine protease inhibitors of the present invention is dependent on the particular application thereof. Examples of such modes of administration include intravenous or intraperitoneal injection, intracoronary infusion, topical application and aerosol inhalation.

The following examples are provided for illustrative purposes only and are in no way intended to limit the scope of the present invention.

EXAMPLE 1

t-PA MUTANTS

Although the technology described in this example is directed to the use of t-PA as the serine protease and PAI-1 as the cognate serine protease inhibitors, other serine proteases of the chymotrypsin superfamily, such as those described above, and their cognate inhibitors, such as those described above, could easily and readily be employed

using the techniques described herein without departing from the spirit and scope of this invention.

A. Selection of t-PA Sites for Mutagenesis

To test the hypothesis that residues Arg₃₀₄ and (296^{KHRRSPG}₃₀₂) of t-PA interact with PAI-1, oligonucleotide-mediated mutagenesis was used to produce the three mutant forms of t-PA shown in Table IX below.

Table IX

wild-type t-PA	FAKHRRSPGERFLC
t-PA(Arg ₃₀₄ ->S)	FAKHRRSPGESFLC
t-PA(Arg ₃₀₄ ->E)	FAKHRRSPGEEFLC
t-PA(Del ₂₉₆₋₃₀₂)	FA.....ERFLC

Mutant t-PA(Del₂₉₆₋₃₀₂) lacks the seven amino acid insertion discussed above which is not found in trypsin, and was constructed so as to completely remove a portion of the t-PA sequence which interacts with the cognate serine protease inhibitor, PAI-1. Mutants t-PA(R₃₀₄->S) and t-PA(R₃₀₄->E) contain substitutions of Ser and Glu, respectively, for Arg₃₀₄, and were chosen to selectively alter the positively-charged Arg residue and eliminate its interaction with the cognate serine protease inhibitor, PAI-1. A variety of other substitutions can be made for R₃₀₄ which would produce a t-PA with reduced susceptibility to its cognate serine protease inhibitor due to a lack of charged-pair interaction. For example, point mutations that convert the positively-charged residues in the loop (residues 296-302) to negatively-charged or neutral amino acids

would be predicted to prevent, reduce or destabilize the interaction between t-PA and PAI-1. A similar result can be obtained by replacing P₃₀₁ with another amino acid, with the exception of Gly (G). Additionally, insertion mutations can be made between residues 304 and 305, or anywhere between residues 296 and 305, so as to insert a series of about 1-6 amino acids that will not interact properly with the PAI-1 residues. Different substitutions and/or combinations of substitutions, insertions and deletions would be expected to affect the interaction between t-PA and PAI-1 to different extents, thereby allowing a variety of t-PAs to be generated with properties appropriate for particular applications or clinical conditions.

B. Oligonucleotide-mediated Mutagenesis of t-PA

Oligonucleotide-mediated mutagenesis of t-PA was carried out essentially as described by Zoller, M. et al, DNA, 3:479-488 (1984) as modified by Kunkel, T., Proc. Natl. Acad. Sci. USA, 82:488-492 (1985); and Kunkel, T. et al, Current Protocols in Molecular Biology, Green Publishing Associates & Wiley Interscience, New York (1987).

First, plasmid pSVT7(RI⁻)/t-PA, which contains a cloned copy of the cDNA encoding full-length human t-PA, was prepared as described by Sambrook, J. et al, Mol. Biol. Med., 3:459-481 (1986). pSVT7(RI⁻)/t-PA is a derivative of pSVT7 (Bird, P.M. et al, J. Cell Biol., 105:2905-2914 (1987)) (see Figure 3).

pSVT7 was constructed from pKC3. pKC3 is a derivative of pko (Van Doren, K. et al, J. Virol., 50:606-614 (1984)) in which the pBR322-derived sequences from the AvaI site to the EcoRI site (which

contain the origin of replication and the β -lactamase gene) have been replaced by those of pUC 8 (Messing, J., Meth. Enzymol., 101:20-78 (1983)). In addition, a polylinker has been inserted into the unique HindIII site and the PvuII site upstream of the SV40 origin has been converted into a ClaI site. Vector pSVT7 was obtained by inserting a 20 base pair fragment containing a bacteriophage T7 RNA polymerase-specific promoter (Pharmacia Fine Chemicals, Piscataway, NJ) into the unique StuI site of pKC3. This StuI site lies within sequences derived from the early region of SV40 at nucleotide 5190 in the SV40 sequence and approximately 30 base pairs downstream from the point of initiation of the early transcript (Tooze, J. et al, DNA Tumor Viruses, Cold Spring Harbor Press, page 813 (1981)).

Then, the single EcoRI site was removed from pSVT7 by filling the recessed 3'-ends with the Klenow fragment of E. coli DNA polymerase. The resulting expression vector was designated pSVT7(RI⁻) (see Figure 3).

Next, cDNA coding for wild-type t-PA was excised from plasmid pL611 (Sambrook, J. et al, Mol. Biol. Med., 3:459-481 (1986); provided by Genetics Institute, Boston, MA) and inserted into pSVT7(RI⁻). pL611 contains, immediately upstream from the initiating AUG codon of t-PA, a synthetic oligonucleotide that introduces cleavage sites for NcoI and BamHI. Approximately 280 base pairs downstream of the TGA termination codon, a BalI site lies within the 3' untranslated sequence of the t-PA cDNA. XbaI linkers were added to the approximately 1965 base pair NcoI-BalI fragment of t-PA DNA that was excised from plasmid pL611. This NcoI-BalI fragment contains the sequences that code for the complete t-PA protein but lacks sequences

corresponding to (i) the distal 3'-untranslated region of t-PA mRNA and (ii) all of the 5'-untranslated sequences of t-PA mRNA, i.e., the sequences between a SalI site and the initiating ATG codon (Pennica, D. et al, Nature, 301:214-221 (1983)). The fragment of t-PA cDNA carrying XbaI sites at each end (Sambrook, J. et al, Mol. Biol. Med., 3:459-481 (1986)) was used to generate pSVT7/t-PA (see Figure 3). The approximately 1970 base pair DNA fragment was excised from the resulting plasmid by digestion with XbaI, purified by 0.8% (w/v) agarose gel electrophoresis and inserted into the XbaI site of plasmid pSVT7(RI⁻) so that the sequences coding for the N-terminus of t-PA were placed immediately downstream of the bacteriophage T7 and SV40 early promoters. The resulting plasmid was designated pSVT7(RI⁻)/t-PA (see Figure 3).

Then, pSVT7(RI⁻)/t-PA was digested to completion with EcoRI. The 472 base pair fragment (nucleotides 842- 1314 which encodes the region covering amino acids 206 to 364) of t-PA was purified by 1.2% (w/v) agarose gel electrophoresis. This fragment was then ligated with replicative-form DNA of the bacteriophage M13 vector M13mpl8 (Yanisch-Perron, C. et al, Gene, 33:103-119 (1985)) which had previously been digested with EcoRI and dephosphorylated with calf intestinal alkaline phosphatase (see Figure 3).

Unless otherwise specified, these and other standard recombinant DNA procedures described herein were carried out as described in (i) Maniatis, T. et al, Molecular Cloning: A Laboratory Manual, 1st Edition, Cold Spring Harbor (1982) and (ii) Meth. Enzymol., Volume 152, Ed. Berger, S. et al, Academic Press, New York (1987).

The ligated DNA was transfected into E. coli strain TG-1 (Gibson, T., Thesis, University of

Cambridge, England (1984)). White plaques formed by recombinant bacteriophages were picked and the presence of the appropriate 472 base pair EcoRI fragment was verified by restriction mapping, Southern hybridization and DNA sequencing.

Mutations in the 472 base pair EcoRI fragment were introduced using a 5'-phosphorylated synthetic mutagenic primer as described by Kunkel, T. et al, Proc. Natl. Acad. Sci. USA, 82:488-492 (1985); and Kunkel T., Meth. Enzymol., 154:367-382 (1987)). The sequences of the three mutagenic primers employed to construct the t-PA mutants were:

t-PA(R ₃₀₄ ->S)	5' GCCCGGAGAGTCGTTCTGTGC ³
t-PA(R ₃₀₄ ->E)	5' GCCCGGAGAGGAGTTCTGTGC ³
t-PA(Del ₂₉₆₋₃₀₂)	5' GCCATCTTTGCCGAGCGGTTCTGC ³

The above protocol uses a DNA template, produced in a strain of E. coli that is dut⁻, ung⁻, i.e., strain CJ236 (Kunkel, T. et al, Proc. Natl. Acad. Sci. USA, 82:488- 492 (1985); and Kunkel, T., Meth. Enzymol., 154:367-382 (1987)). The DNA template contains a small number of uracil residues in place of thymine.

After the mutagenic primer was extended in vitro, the partially-filled circular DNA was transfected into a strain of E. coli that is dut⁺, ung⁺, i.e., TG-1 (Gibson, T., Thesis, University of Cambridge, England (1984)). The uracil residues in the template strand were then removed in vivo by the action of the enzyme uracil N-glycosylase. This generated lethal lesions in the template strand and therefore allowed rapid and efficient recovery of mutants.

More specifically, the uracil-containing template DNAs were annealed to the 5' phosphorylated

mutagenic primers shown above. Extension of the primer was carried out for 12-16 hours at 15°C using the Klenow fragment of E. coli DNA polymerase. The newly-synthesized strand was ligated to the 5' end of the mutagenic primer with bacteriophage T4 DNA ligase, forming a circle bearing a mismatch. The resulting DNA was used to transfect E. coli strain TG-1 (Gibson, T., Thesis, University of Cambridge, England (1984)) and single-stranded DNA was prepared from a number of the plaques. These DNAs were completely sequenced. The double-stranded replicative form of the DNAs of proven mutants was then isolated and the mutated 472 base pair fragments were isolated by digestion with EcoRI and electrophoresis through 1.2% (w/v) agarose gels. As described in detail below, these fragments containing mutations were then used to reconstruct versions of the t-PA cDNA that encoded the t-PA mutants of interest.

C. Construction of Expression Vectors for Mutant t-PAs

Mutants of t-PA in plasmid pSVT7(RI⁻)/t-PA were constructed as follows: The central 472 base pair EcoRI fragment of t-PA cDNA was removed from plasmid pSVT7(RI⁻)/t-PA by digestion with EcoRI and by 1.2% (w/v) agarose gel electrophoresis. The remaining linear fragment of the plasmid DNA was then ligated to the versions of the 472 base pair fragment created by oligonucleotide-mediated mutagenesis (see Figure 3). The resulting plasmids were designated pSVT7(RI⁻)/t-PA(R₃₀₄⁻→S), pSVT7(RI⁻)/t-PA(R₃₀₄⁻→E) and pSVT7(RI⁻)/t-PA(Del₂₉₆₋₃₀₂).

E. coli strain DH-1 (Hanahan, D. et al, DNA Cloning, Volume 1, Ed. Glover, D.M., I.R.L. Press, Oxford, pages 109-135 (1985)) was transformed with the

above mutant plasmids and the resulting strains were designated pSVT7(RI⁻)/t-PA(R₃₀₄->S) [DH-1]; pSVT7(RI⁻)/t-PA(R₃₀₄->E) [DH-1]; and pSVT7(RI⁻)/t-PA(Del₂₉₆₋₃₀₂) [DH-1], respectively. The presence of the correct fragment was confirmed by hybridization to the appropriate radiolabeled mutagenic oligonucleotide and the orientation of the fragment was verified by restriction mapping and DNA sequencing, using the appropriate mutagenic oligonucleotides as primers.

pSVT7(RI⁻)/t-PA(R₃₀₄->S) [DH-1],
pSVT7(RI⁻)/t-PA(R₃₀₄->E) [DH-1] and
pSVT7(RI⁻)/t-PA(Del₂₉₆₋₃₀₂) [DH-1] have been deposited at the American Type Culture Collection under ATCC Nos. 67894, 67896 and 67895, respectively.

D. Transfection of COS Cells

Next, approximately 10⁶ COS cells (Gluzman, Y. et al, Cell, 23:175-182 (1981)) per 100 mm dish were transfected with 1.0 µg of the appropriate plasmid DNA purified by the alkaline lysis procedure (Maniatis, T. et al, Molecular Cloning: A Laboratory Manual, 1st edition, Cold Spring Harbor (1982)). More specifically, the medium was removed from the COS cells by aspiration and the monolayers were washed once with 5.0 ml of Dulbecco's medium (GIBCO, Inc.) containing 10 mM HEPES (pH 7.15) (Sigma Chemical Co.). After removal of the wash solution, the plasmid DNA was then added to the monolayers in a volume of 1.5 ml of wash solution containing 300 µg of DEAE-dextran (Pharmacia, Inc.). The monolayers were then incubated for 1 hour at 37°C in an humidified atmosphere containing 6.0% CO₂. The monolayers were agitated gently every 20 minutes during this period. After the monolayers had been exposed to the plasmid DNA for 1 hour, they were washed once with Dulbecco's medium containing

10 mM HEPES (pH 7.15) and then 10 ml Dulbecco's medium containing 10% (v/v) fetal bovine serum (GIBCO, Inc.) and 100 μ M chloroquine (Sigma Chemical Co.) was added. The monolayers were then incubated at 37°C for 4 hours as described above, and washed twice with 5.0 ml of Dulbecco's medium lacking fetal bovine serum but containing 10 mM HEPES (pH 7.15). 10 ml of Dulbecco's medium containing 10% (v/v) fetal bovine serum was then added and the monolayers were incubated at 37°C as described above for 12 hours. Then, the monolayers were washed three times each with 5.0 ml with Dulbecco's medium lacking fetal bovine serum and incubated at 37°C in the same medium for a further 36-60 hours. Mock-transfected cells were treated identically except that plasmid DNA was omitted from the solution containing DEAE-dextran. At the end of the incubation period, the supernatant medium was collected from the cells and analyzed as described below.

E. Quantitation of Wild-Type and Mutant t-PAs by Solid-Phase Radioimmunoassay

A solid-phase radioimmunoassay was performed essentially as described for influenza hemagglutinin (Gething, M.J. et al, Nature, 293:620-625 (1981)) using the IgG fraction of rabbit antisera raised against purified human t-PA so as to quantitate the amounts of wild-type and mutant t-PAs produced in the COS cells. The concentration of t-PA determined by this method was between 0.5 and 1.0 μ g/ml.

F. Enzymatic Assay of Wild-Type and Mutant t-PAs

An indirect chromogenic assay was carried out so as to determine the activities of the wild-type and

mutant t-PAs produced in the COS cells. In this assay, free p-nitroaniline is released from the chromogenic substrate Spectrozyme PL (H-D-norleucylhexahydrotyrosyl-lysine-p-nitroanilide diacetate salt) (American Diagnostica, Inc.) by the action of plasmin generated by the action of t-PA on plasminogen. The release of free p-nitroaniline was measured spectrophotometrically at OD_{405 nm}.

More specifically, 100 µl reaction mixtures comprising 150-200 pg of the t-PA to be tested, 0.4 mM of Spectrozyme PL, 0.1 µM of Lys-plasminogen (American Diagnostica, Inc.) and 0.5-25 µg/ml of soluble fibrin (Des-A-fibrinogen) (American Diagnostica, Inc.) in a buffer comprising 50 mM Tris-HCl (pH 7.5), 0.1 M NaCl, 1.0 mM EDTA and 0.01% (v/v) Tween 80 were incubated at 37°C in 96-well, flat-bottomed microtiter plates (Costar, Inc.) and the OD_{405 nm} was measured with a Bio-tek microplate reader (Model EL310) at 15 or 30 minute intervals over a 2 hour period. Aliquots of buffer or appropriately-diluted samples of medium from mock-transfected cells were analyzed as controls and the OD values obtained (<0.01 unit) were subtracted from the corresponding test values. Delta OD values were measured as the change in optical density between 30 minutes and 60 minutes, i.e., following the lag phase of the reaction and the complete conversion of single-chain t-PA to the two-chain form. Under the conditions used in the standard assay (0.1 µM of Lys-plasminogen and 25 µg/ml of Des-A-fibrinogen), soluble fibrin stimulated the activity of t-PA 20-40 fold. The results are shown in Figure 4.

As shown in Figure 4, all three of the above-described t-PA mutants of the present invention were found to be enzymatically active and their

specific activities were not found to be significantly different from that of wild-type t-PA. In addition, the above-described t-PA mutants of the present invention were found to respond to varying concentrations of Des-A-fibrinogen in a manner similar to that of wild-type t-PA. The maximal stimulation by Des-A-fibrinogen was 20-40 fold. This is in agreement with the observations of others on wild-type t-PA using a Des-A-fibrinogen preparation (Karlan, B. et al, Biochem. Biophys. Res. Comm., 142:147-154 (1987)). In each case, half-maximal stimulation occurred when Des-A-fibrinogen was present at a concentration of approximately 1.0 $\mu\text{g/ml}$.

Next, the K_m and K_{cat} values of the wild-type and mutant t-PAs were determined by assaying the various forms of the enzyme in the presence of saturating concentrations of Des-A-fibrinogen (25 $\mu\text{g/ml}$) and different concentrations (from 0.02-0.16 μM) of the substrate, Lys-plasminogen. The results are shown in Table X below.

Table X

<u>Enzyme</u>	<u>K_m (μM)</u>	<u>K_{cat} (s^{-1})</u>
Wild-type t-PA	0.024	0.22
t-PA(R ₃₀₄ ->S)	0.019	0.23
t-PA(R ₃₀₄ ->E)	0.023	0.22
t-PA(Del ₂₉₆₋₃₀₂)	0.029	0.17

As shown in Table X above, the K_m and K_{cat} values for the different t-PA mutants were similar to one another. The values are also similar to values for wild-type t-PA reported by Boose, J. et al,

Biochem., 28:635-643 (1989); and Hoylaerts, M. et al, J. Biol. Chem., 257:2912-2919 (1982).

The data shown in Figure 4 and Table X demonstrate that (i) deletion of amino acids 296-302 of t-PA and (ii) substitution of Ser or Glu for Arg at position 304 have little effect on the ability of t-PA to activate plasminogen and to be stimulated by soluble fibrin fragments.

To test whether deletion of amino acids 296-302 and substitution of Arg₃₀₄ affects the interaction of t-PA with PAI-1, approximately 250 pg (3.8 femtomoles) each of the wild-type and mutant t-PAs were pre-incubated for 20 minutes with 0-480 femtomoles of partially-purified recombinant PAI-1. The residual enzymatic activity was then measured using the indirect chromogenic assay described above. The partially-purified recombinant PAI-1 was obtained as described in Example 2 below. The results are shown in Figure 5.

As shown in Figure 5, all three of the t-PA mutants of the present invention behave quite differently from wild-type t-PA. That is, under conditions where wild-type t-PA (*) is completely inhibited by PAI-1 (24 femtomoles of PAI-1), the deletion mutant t-PA(Del₂₉₆₋₃₀₂) (•) retains approximately 95% of its activity. Only when high concentrations of PAI-1 are present (480 femtomoles of PAI-1), does mutant t-PA(Del₂₉₆₋₃₀₂) (•) display any significant diminution of enzymatic activity. The two substitution mutants, i.e., t-PA(R₃₀₄->S) (o) and t-PA(R₃₀₄->E) (□), also are resistant to inhibition by PAI-1, although to different extents. Also, as shown in Figure 5, the two substitution mutants containing Ser or Glu instead of Arg require approximately 4 and 25 times more PAI-1,

respectively, for half-maximal inhibition of enzyme activity than does wild-type t-PA.

The above data indicate that amino acids 296-302 and 304 are not involved in catalytic functions of t-PA, but play an important role in the interaction of the enzyme with its cognate serine protease inhibitor, PAI-1. Using the structure of trypsin as a model, these amino acids are predicted to map near the active site of the serine protease, some distance from the catalytic triad. Thus, the area of contact between t-PA and PAI-1 is more extensive than the interaction between t-PA and its true substrate plasminogen.

In order to determine whether or not mutant t-PA(Del₂₉₆₋₃₀₂) also exhibited resistance to the complex mixture of serine protease inhibitors present in human plasma, a 1:100 dilution of human plasma was substituted for the partially-purified recombinant PAI-1 in the protocol described above. Under these conditions, approximately 70% of the activity of the wild-type t-PA was inhibited while the activity of t-PA(Del₂₉₆₋₃₀₂) was unaffected.

In addition, wild-type t-PA and t-PA(Del₂₉₆₋₃₀₂) were incubated with undiluted human plasma and then the mixtures were acidified to pH 5.0 and centrifuged for 5 minutes at 12,000 x g. The clarified supernatants were diluted and assayed for residual t-PA activity, which totalled 90% for the mutant t-PA(Del₂₉₆₋₃₀₂) and 20% or less for the wild-type t-PA. The above results demonstrate that mutant t-PA(Del₂₉₆₋₃₀₂) is resistant to the complex mixture of serine protease inhibitors present in human plasma and therefore is believed to be superior to wild-type t-PA as a therapeutic agent.

G. Additional t-PA Mutants

The data presented in Section F above demonstrate that residues 296-302 and 304 of t-PA play an important role in interaction of the enzyme with the cognate inhibitor, PAI-1, but not with the substrate, Lys-plasminogen. Modeling of the catalytic domain of t-PA based on the known structure of trypsin suggests that residues 296-302 form a surface loop at the edge of the enzyme's active site. This loop is highly positively charged. As discussed above in Sections A and F, it has been proposed in the present invention that the effect of this region may be mediated by its formation of electrostatic bonds with PAI-1. To test this hypothesis, each of the charged residues within the loop were altered and the effect of these mutations upon the enzyme's interaction with PAI-1 was assessed as described below. If the positively charged residues in the loop form salt bridges with a complementary region of the serine protease inhibitor, PAI-1, then their substitution by negatively charged residues would be expected to be disruptive of interactions between t-PA and PAI-1 due to the juxtaposition of the side chains of similarly charged residues during the association of these two proteins.

More specifically, site directed mutagenesis was carried out as described above in Section B and used to construct cDNAs that encoded t-PA mutants in which Lys₂₉₆, Arg₂₉₈, or Arg₂₉₉ had been replaced by a Glu residue. A cDNA encoding a triple mutant of t-PA in which all three of these residues were replaced by Glu was also constructed. Two additional cDNA's were produced; one encodes a t-PA mutant in which His₂₉₇ has been replaced by a Tyr residue while the other encodes an enzyme in which Pro₃₀₁ has been replaced by Gly.

The sequences of the six mutagenic primers employed to construct these t-PA mutants were:

t-PA(K₂₉₆->E) : 5'-ATCTTTGCCGAGCACAGGA-3'
 t-PA(H₂₉₇->Y) : 5'-TTTGCCAAGTACAGGAGGT-3'
 t-PA(R₂₉₈->E) : 5'-GCCAAGCACGAGAGGTCGCCC-3'
 t-PA(R₂₉₉->E) : 5'-AAGCACAGGGAGTCCCCCGG-3'
 t-PA(P₃₀₁->G) : 5'-AGGAGGTCGGGCGGAGAGCG-3'
 t-PA(K₂₉₆, R₂₉₈, R₂₉₉->
 E, E, E) :

5'-GCCATCTTTGCCGAGCACGAGGAGTCGCCCCGAGA-3'

cDNAs encoding the mutated enzymes t-PA(K₂₉₆->E), t-PA(H₂₉₇->Y), t-PA(R₂₉₈->E) and t-PA(P₃₀₁->G) were ligated into the transient expression vector pSVT7(RI⁻), as described above.

cDNAs encoding the mutated enzymes t-PA(K₂₉₆, R₂₉₈, R₂₉₉-> E, E, E) and t-PA(R₂₉₉->E) were ligated into the transient expression vector pSTE. pSTE is a derivative of pSVT7 and was constructed by replacement of the 350 bp ClaI-HindIII promoter/origin fragment of pSTV7 with the 418 bp HpaII-HindIII fragment from the promoter/origin region of SV40 csl085 (DiMaio, D. et al, J. Mol. Biol., 140:129-142 (1980)).

The resulting plasmids were designated pSVT7(RI⁻)/t-PA(K₂₉₆->E), pSVT7(RI⁻)/t-PA(H₂₉₇->Y); pSVT7(RI⁻)/t-PA(R₂₉₈->E); pSTE/t-PA(R₂₉₉->E); pSVT7(RI⁻)/t-PA(R₃₀₁->G); and pSTE/t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E).

E. coli strain DH-1 (Hanahan, D. et al, DNA Cloning, Volume 1, Ed. Glover, D.M., I.R.L. Press, Oxford, pages 109-135 (1985)) was transformed with the above mutant plasmids and the resulting strains

were designated pSVT7(RI⁻)/t-PA(K₂₉₆->E) [DH-1], pSVT7(RI⁻)/t-PA(H₂₉₇->Y) [DH-1]; pSVT7(RI⁻)/t-PA(R₂₉₈->E) [DH-1]; pSTE/t-PA(R₂₉₉->E) [DH-1]; pSVT7(RI⁻)/t-PA(R₃₀₁->G) [DH-1]; and pSTE/t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E) [DH-1], respectively. The presence of the correct fragment was confirmed by hybridization to the appropriate radiolabeled mutagenic oligonucleotide and the orientation of the fragment was verified by restriction mapping and DNA sequencing, using the appropriate mutagenic oligonucleotides as primers.

pSVT7(RI⁻)/t-PA(R₂₉₈->E) [DH-1]; pSTE/t-PA(R₂₉₉->E) [DH-1]; and pSTE/t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E) [DH-1] have been deposited at the American Type Culture Collection under ATCC Nos. 68157, 68154, and 68153, respectively.

The above plasmid DNAs were then used to transfect COS cells as described above. Assays were performed as described above with both dilutions of the resulting conditioned media (typically 1:300) and with immuno-purified enzymes.

Next, the K_m and K_{cat} values of the wild-type and mutant t-PAs were determined by assaying the various forms of the enzyme in the presence of saturating concentrations of Des-A-fibrinogen (25 µg/ml) and different concentrations (from 0.02-0.16 µM) of the substrate, Lys-plasminogen. The results are shown in Table XI below.

Table XI

<u>Enzyme</u>	<u>K_m (μM)</u>	<u>K_{cat} (s⁻¹)</u>
Wild-type t-PA	0.024	0.22
t-PA(K ₂₉₆ ->E)	0.026	0.22
t-PA(H ₂₉₇ ->Y)	0.017	0.14
t-PA(R ₂₉₈ ->E)	0.027	0.24
t-PA(R ₂₉₉ ->E)	0.033	0.26
t-PA(P ₃₀₁ ->G)	0.027	0.24
t-PA(K ₂₉₆ , R ₂₉₈ , R ₂₉₉ -> E, E, E)	0.027	0.24

As shown in Table XI above, none of the mutations discussed above substantially altered the t-PA's interaction with its substrate.

Similarly, the data presented in Figure 6 suggests that the mutations have not altered t-PA's interaction with its positive effector, Des-A-fibrinogen. By contrast, the data presented in Figure 7 indicates clear differences in the behavior of wild-type t-PA and some of the mutant t-PAs. Specifically, the ability to interact normally with the serpin, PAI-1, has been substantially changed for three of the mutant t-PAs, i.e., t-PA(R₂₉₈->E), t-PA(R₂₉₉->E), and t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E). The behavior of the triple mutant is particularly striking; even after pre-incubation with a greater than 200-fold molar excess of PAI-1, the triple mutant shows no loss of activity. These findings support the proposal that the surface loop of t-PA, i.e., residues 296-302, interacts specifically with the cognate inhibitor, PAI-1, and suggest that this interaction involves Arg₂₉₈ and Arg₂₉₉. These observations are consistent with the hypothesis that the specific interactions between t-PA and PAI-1

involve electrostatic bonds. The residues of t-PA involved in these interactions are Arg₂₉₈, Arg₂₉₉, and Arg₃₀₄.

EXAMPLE 2

PAI-1 MUTANTS

Although the technology described in this example is directed to the use of t-PA as the serine protease and PAI-1 as the serine protease inhibitor, other serine proteases of the chymotrypsin superfamily, such as those described above, and other serine protease inhibitors, such as those described above, could easily and readily be employed using the techniques described herein without departing from the spirit and scope of this invention.

A. Expression, Purification and Assay of Glycosylated PAI-1 in Eukaryotic Cells

Two different cDNA clones derived from the 3.2 kb and 2.2 kb mRNAs encoding PAI-1 (Ny, T. et al, Proc. Natl. Acad. Sci. USA, 83:6776-6780 (1986); and Pannekoek, H. et al, EMBO J., 5:2539-2544 (1986)) were used to construct a full length cDNA in a mammalian expression vector. The first clone, lambda PAI-1, was a truncated version of the cDNA that was obtained by screening a human placental cDNA library (provided by Dr. Carol Mendelson, Department of Biochemistry, Southwestern Medical Center, Dallas, TX) with a synthetic oligonucleotide corresponding to the following sequence of 8 amino acids of PAI-1 (AVDQLTRL) (Ny, T. et al, Proc. Natl. Acad. Sci. USA, 83:6776-6780 (1986); and Pannekoek, H. et al, EMBO J., 5:2539-2544 (1986)). The fragment of DNA released from this clone by digestion with EcoRI corresponded to nucleotides 147-2013 of the PAI-1 sequence reported by Ny, T. et al, Proc. Natl. Acad.

Sci. USA, 83:6776-6780 (1986). This fragment was subcloned into the plasmid vector pUC 18 (Yanisch-Perron, C. et al, Gene, 33:103-119 (1985)) to yield the recombinant plasmid pPAI-1. The insert from this plasmid was then used to screen a human endothelial cell cDNA library that was constructed in bacteriophage lambda gtl1 (Huynh, T. et al, DNA Cloning, Volume 1, Ed. Glover, D.M., I.R.L. Press, Oxford, pages 49-88 (1985)). One of the cDNA clones isolated in this fashion, i.e., lambda PAI-1-11A, carries an insert that is identical in sequence to the PAI-1 cDNA previously reported (Pannekoek, H. et al, EMBO J., 5:2539-2544 (1986)) except for the presence of two additional nucleotides at the 5' end. The EcoRI-BglII fragment derived from the 5' end of this clone, nucleotides 52-1479, was fused to the 3' BglII-EcoRI fragment of pPAI-1 to yield pPAI-1-RBR.

The SV40 vector used to express PAI-1 in mammalian cells was constructed as follows. The termini of the EcoRI fragment released from pPAI-1-RBR were filled with the Klenow fragment of E. coli DNA polymerase, ligated to synthetic XbaI linkers and inserted in place of the t-PA fragment in the plasmid pSV/t-PA3 to yield pSV_L-PAI-1 (Sambrook, J. et al, Mol. Biol. Med., 3:459-481 (1986)). Stocks of SV_L-PAI-1 were generated and propagated as described by Doyle, C. et al, J. Cell. Biol., 105:704-714 (1985).

PAI-1 clones described previously by Pannekoek, H. et al, EMBO J., 5:2539-2544 (1986) and Ginsberg, D. et al, J. Clin. Invest., 78:1673-1680 (1986) encode a PAI-1 protein identical in sequence to that encoded by pPAI-1-RBR and could have been used in place of pPAI-1-RBR to construct SV_L-PAI-1.

Monolayers of CV-1 simian cells were grown at 37°C and then infected with SV_L-PAI-1. After

24 hours, the medium was replaced with serum-free Dulbecco's medium (GIBCO, Inc.) and incubation was continued for a further 48 hours. The supernatant medium containing secreted PAI-1 was then filtered through an 0.45 micron filter (Nalge Co.). Nonidet P40 (Sigma Chemical Co.) and 1.0 M sodium phosphate (pH 7.2) buffer were then added to concentrations of 0.1% (v/v) and 10 mM, respectively. The stabilized medium was applied to an affinity column of concanavalin A-Sepharose 4B (1.0 ml packed bed volume), which had been equilibrated with a buffer comprising 20 mM sodium phosphate (pH 7.2), 135 mM NaCl, 7.0 mM KCl (hereinafter "PBS"), at a flow rate of 50 ml per hour. The column was successively washed with 25 volumes of PBS containing 0.1% (v/v) of Nonidet P40, 25 volumes of PBS containing 0.1% (v/v) of Nonidet P40 and 1.0 M NaCl and finally with 10 volumes of 20 mM sodium phosphate buffer (pH 7.2). The bound PAI-1 was specifically eluted with 0.5 M alpha-methyl-D-glucoside (Sigma Chemical Co.) in 20 mM sodium phosphate buffer (pH 7.2). Fractions containing PAI-1 (as assayed by inhibition of urokinase from Calbiochem, Inc. in the indirect chromogenic assay described above) were pooled. Nonidet P40 was then added to a concentration of 0.1% (v/v) and 0.57 g of guanidine hydrochloride (U.S. Biochemicals) was added per ml of pooled eluate. The partially-purified PAI-1 thus obtained was dialyzed against a buffer comprising 20 mM sodium phosphate (pH 7.2) and 10% (v/v) glycerol, and was stored in aliquots at -80°C until used.

The PAI-1 prepared in this manner contained 40 µg/ml of total protein (assayed by Bradford's reagent purchased from BioRad Inc.) and 15 µg/ml of PAI-1, as assayed by staining of 12.5% (w/v)

SDS-polyacrylamide gels. Titration against urokinase (itself titrated to be 52% active using ^3H -diisopropylfluorophosphate (NET-065 from New England Nuclear, Inc.)) revealed that the PAI-1 prepared as described herein was 16.6% active and that the concentration of active PAI-1 was 48 nM.

B. Selection of PAI-1 Sites for Mutagenesis

To test the hypothesis that residues Glu₃₅₀ and Glu₃₅₁ of PAI-1 interact with t-PA, oligonucleotide directed mutagenesis was used to produce the two mutant forms of PAI-1 shown in Table XII below.

Table XII

	346.	• 355
wild-type PAI-1	R M A P E E I I M D	
	.	
PAI-1(E ₃₅₀ ->R)	R M A P R E I I M D	
	.	
PAI-1(E ₃₅₁ ->R)	R M A P E R I I M D	

Mutants PAI-1(E₃₅₀->R) and PAI-1(E₃₅₁->R) contain substitutions of Arg for Glu₃₅₀ and Glu₃₅₁, respectively, and were chosen to selectively alter the negatively-charged Glu residues to positively-charged Arg residues and promote potential interactions with the negatively-charged Glu₃₀₄ residue present in t-PA(R₃₀₄->E). A variety of other substitutions could be made for Glu₃₅₀ which would produce a PAI-1 with increased interaction with, e.g., the t-PA(R₃₀₄->E) mutant, provided those substitutions were complementary to the specific mutations introduced in residue Arg₃₀₄ of t-PA without departing from the spirit and scope of the present invention.

C. Oligonucleotide-Mediated Mutagenesis
of PAI-1

First, it was necessary to construct a PAI-1 expression plasmid, designated plasmid pPAIST7, which provides for the direct expression of methionyl-PAI-1 while eliminating the signal sequence and the 3'-untranslated region of the cDNA sequence from the expression vector. To achieve this, synthetic DNA linkers were used to reconstruct both ends of the PAI-1 cDNA coding sequence and to introduce an ATG protein synthesis initiation codon immediately before the triplet encoding the first residue of mature PAI-1. In addition, to facilitate the insertion of the cDNA coding region into plasmid pBR322, the linkers were designed to generate EcoRI and HindIII restriction endonuclease recognition sites at the 5' and 3' termini, respectively, of the PAI-1 cDNA fragment.

More specifically, plasmid pPAIST7 was obtained by digesting pPAI-1-RBR with ApaLI and PflMI. The resulting 1127 bp fragment, containing 2 bp of the codon for residue 1 of PAI-1 and the full coding sequence for residues 2-376 of the 379 residue protein, was purified by gel electrophoresis. Next, synthetic linkers (10 bp at the 5' end and 13 bp at the 3' end) were ligated with the 1127 bp ApaLI and PflMI DNA fragment, digested with EcoRI and HindIII, and the 1146 bp EcoRI- and HindIII-digested DNA fragment was isolated by gel electrophoresis. This fragment was then cloned into EcoRI- and HindIII-digested pBR322.

To initiate construction of an expression plasmid, the subclone was digested with EcoRI and the linear plasmid dephosphorylated with bacterial alkaline phosphatase. Then, using the 360 bp EcoRI DNA fragment from pC5A-48 (Franke, A. et al, Meth.

Enzymol., 162:653-668 (1988)), containing the trp promoter and ribosome binding site, a PAI-1 expression plasmid was constructed by ligating the two fragments together. Next, E. coli were transformed with the resulting plasmids as described by Maniatis, T. et al, Molecular Cloning: A Laboratory Manual, 1st Edition, Cold Spring Harbor (1982). The plasmid DNA of the resulting transformants was screened by restriction analysis with HindIII for the presence and orientation of the trp promoter fragment. Multiple transformants were identified containing plasmids having the PAI-1 gene adjacent to the trp promoter in the configuration required for direct expression of the inhibitor. One such plasmid was designated pPAIST7.

The SalI-HindIII fragment of plasmid pPAIST7, containing the nucleotide sequences of PAI-1 encoding amino acid residues Val₂₈₄ to Pro₃₇₉, was ligated into SalI-HindIII digested replicative form M13mp18 (see Figure 8). The ligated DNA was transfected into E. coli strain TG-1. White plaques formed by recombinant bacteriophage were picked and the presence of the appropriate 290 base pair SalI-HindIII fragment was verified by Southern hybridization, restriction mapping and DNA sequencing.

Mutations in the 290 base pair SalI-HindIII fragment were introduced using 5'-phosphorylated synthetic mutagenic oligonucleotide primers as described for t-PA above (see Figure 8). The sequences of the two mutagenic primers employed to construct these PAI-1 mutants were:

PAI-1(E₃₅₀->R) : 5' TGATGATCTCTCTTGGGGC 3'

PAI-1(E₃₅₁->R) : 5' CCATGATGATTCTCTCGGGG 3'

The sequences of the resulting mutant SalI-HindIII fragments of PAI-1 DNA were completely determined. The doubled-stranded replicative form of the DNAs of proven mutants was then isolated and the mutated 290 base pair SalI-HindIII fragments were isolated by SalI-HindIII digestion and electrophoresis through 6.0% (w/v) non-denaturing polyacrylamide gels. As described in detail below, these fragments, containing mutations, were then used to reconstruct versions of the PAI-1 cDNA that encoded the PAI-1 mutants of interest.

D. Construction of Expression Vectors for Mutant PAI-1's

Mutants of PAI-1 in plasmid pPAIST7HS (a derivative of plasmid pPAIST7 lacking the HindIII site at nucleotide pair 1 and the SalI site at nucleotide pair 2106, which was constructed to facilitate the exchange of mutated SalI to HindIII fragments in the PAI-1 cDNA coding sequences, (see Figure 8) were constructed as follows:

The central 290 base pair SalI to HindIII fragment of the PAI-1 cDNA was removed from plasmid pPAIST7HS by digestion with SalI and HindIII and by 1.0% (w/v) agarose gel electrophoresis. The remaining linear-fragment of the vector DNA was then ligated to the mutant versions of the 290 base pair SalI to HindIII fragment described above which had been generated by oligonucleotide-directed mutagenesis (see Figure 8). The resulting plasmids were designated pPAIST7HS(E₃₅₀->R) and pPAIST7HS(E₃₅₁->R).

E. coli strain DH-1 (Hanahan, D. et al, DNA Cloning, Volume 1, Ed. Glover, D.M., I.R.L. Press, Oxford, pages 109-135 (1985)) was transformed with the above mutant plasmids and the resulting strains

were designated pPAIST7HS [DH-1];
pPAIST7HS(E₃₅₀->R) [DH-1]; and
pPAIST7HS(E₃₅₁->R) [DH-1], respectively. E. coli
strain TG-1 (Gibson, T., Thesis, University of
Cambridge, England (1984)) was transformed with the
above mutant plasmids and the resulting strains were
designated pPAIST7HS [TG-1];
pPAIST7HS(E₃₅₀->R) [TG-1]; and
pPAIST7HS(E₃₅₁->R) [TG-1], respectively. The
presence of the correct fragment was confirmed by
hybridization to the appropriate radiolabeled
mutagenic oligonucleotide and by nucleic acid
sequencing.

pPAIST7HS(E₃₅₀->R) [DH-1]; and
pPAIST7HS(E₃₅₁->R) [DH-1] have been deposited at the
American Type Culture Collection under ATCC Nos.
68155 and 68156, respectively.

E. Expression, Extraction, and Assay of
Wild-Type and Mutant PAI-1s

E. coli strains pPAIST7HS [TG-1],
pPAIST7HS(E₃₅₀->R) [TG-1], and
pPAIST7HS(E₃₅₁->R) [TG-1] were grown overnight at
37°C in Luria-Bertani broth to saturating density.
50 µl of culture were used to inoculate 50 ml of
modified M9 medium (pH 7.4) containing, per liter,
6.0 g of Na₂HPO₄, 3.0 g of KH₂PO₄, 0.5 g of NaCl,
0.5 g of MgSO₄·7H₂O, 1.0 g of NH₄Cl, 5.0 g of
casamino acids, 10.0 g of glucose, 10.0 ml of
glycerol, 1.0 mg of thiamine-HCl, and 25 mg of
ampicillin. Bacterial cultures were grown for
22 hours at 37°C in 250 ml Ehrlenmeyer flasks. Cell
extracts were prepared from cultures as follows.

E. coli were pelleted by centrifugation, washed
in 20 ml of cold 50 mM Tris-HCl (pH 8.0) and 1.0 mM
EDTA by centrifugation, and resuspended in 3.6 ml of

the same buffer on ice. Extraction was accomplished by the addition of 0.4 ml of 10 mg per ml of lysozyme for 20 minutes, 0.1 ml of 10% (v/v) Nonidet P-40 for 10 minutes, and 0.2 ml of 5.0 M NaCl for 10 minutes. The cells were briefly disrupted using the microtip of a sonifier/cell disruptor at 50% duty cycle and setting 7 (Branson Sonic Power Company) to reduce the viscosity before centrifugation at $15,000 \times g$ for 30 minutes at 4°C . Glycerol was added to the clarified bacterial lysates to a concentration of 10% (v/v) and the extracts containing PAI-1 were stored at -80°C in aliquots until used.

Extracts were titrated for active PAI-1 by incubation for 3 hours at 24°C with urokinase as described above for PAI-1 expressed in mammalian cells. Extracts of wild-type PAI-1, PAI-1($\text{E}_{350} \rightarrow \text{R}$), and PAI-1($\text{E}_{351} \rightarrow \text{R}$) contained 803 nM, 593 nM, and 162 nM of active PAI-1, respectively.

Kinetic measurements on the rate of interaction of wild-type and mutant t-PAs with wild-type and mutant PAI-1s were performed at 24°C in 0.1 M Tris-HCl buffer (pH 7.4) containing 0.1 mM EDTA and 0.1% (v/v) Tween 20. The indirect chromogenic assay for t-PA described above was used to determine the residual enzyme activity remaining as a function of time. Under pseudo-first order conditions for an excess of PAI-1 over t-PA, the half-life ($t_{1/2}$) was determined for each inhibitor concentration from the slope of a linear semi-logarithmic plot of residual t-PA activity versus time. The rate constant, k_1 , was then calculated by dividing the apparent rate constant ($k_{\text{app}} = 0.693/t_{1/2}$) by the inhibitor concentration.

The rate of inhibition of 60 pM t-PA was studied under pseudo-first order conditions using inhibitor concentrations ranging from 0.6 to 100 nM. The

t-PA-PAI-1 mixes were preincubated in microtiter plate wells at 24°C for various time periods (from 0 to 30 minutes) before the addition of a mixture of Lys-plasminogen, Spectrozyme PL, and Des-A-fibrinogen to final concentrations of 300 nM, 0.4 nM, and 12.5 µg/ml, respectively. After the addition of substrates, the microtiter plates were incubated at 37°C and the absorbance at 405 nm was monitored for 2 hours to determine the residual t-PA activity.

The approximate rate constants of inhibition ($M^{-1}s^{-1}$) of wild-type and mutant t-PAs by wild-type and mutant PAI-1s are given in Table XIII below.

Table XIII

	wild-type t-PA	t-PA(R ₃₀₄ ->S)	t-PA(R ₃₀₄ ->E)
wild-type PAI-1	1×10^6	3×10^5	1×10^4
PAI-1(E ₃₅₀ ->R)	1×10^6	1×10^6	1×10^6
PAI-1(E ₃₅₁ ->R)	3×10^5	1×10^5	1×10^5

As shown in Table XIII above, both PAI-1(E₃₅₀->R) and PAI-1(E₃₅₁->R) show increased rate constants of interaction with t-PA(R₃₀₄->E) in comparison to wild-type PAI-1, proving that the mutations have restored the ability of PAI-1 to inhibit the serine protease inhibitor-resistant t-PA(R₃₀₄->E).

While this invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications could be made therein without departing from the spirit and scope thereof.

CLAIMS

Claim 1. A mutant of a serine protease of the chymotrypsin superfamily which is resistant to inhibition by its cognate inhibitor.

Claim 2. The mutant as claimed in Claim 1, wherein said serine protease of the chymotrypsin superfamily is selected from the group consisting of t-PA, trypsin, trypsin-like protease, chymotrypsin, plasmin, elastase, u-PA, acrosin, activated protein C, C1 esterase, cathepsin G, chymase, kallikrein, thrombin, and Factors VIIa, IXa, Xa, XIa and XIIa.

Claim 3. The mutant as claimed in Claim 2, wherein said serine protease is t-PA.

Claim 4. The mutant as claimed in Claim 1, wherein said inhibitor is a member selected from the group consisting of the BPTI family, the Kazal family, the SSI family, the serpin family, the soybean trypsin inhibitor (Kunitz) family, the potato inhibitor family, and the Bowman-Birk family.

Claim 5. The mutant as claimed in Claim 4, wherein said inhibitor of the serpin family is selected from the group consisting of PAI-1, PAI-2 and PAI-3, C1 esterase inhibitor, alpha-2-antiplasmin, contrapsin, alpha-1-antitrypsin, antithrombin III, protease nexin I, alpha-1-antichymotrypsin, protein C inhibitor, heparin cofactor II and growth hormone regulated protein.

Claim 6. The mutant as claimed in Claim 5, wherein said serpin is PAI-1.

Claim 7. The mutant as claimed in Claim 1, wherein said mutant is selected from the group consisting of t-PA(R₃₀₄->S), t-PA(R₃₀₄->E), t-PA(Del₂₉₆₋₃₀₂), t-PA(R₂₉₈->E), t-PA(R₂₉₉->E) and t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E).

Claim 8. A gene encoding a mutant of a serine protease of the chymotrypsin superfamily which is resistant to inhibition by its cognate inhibitor.

Claim 9. The gene as claimed in Claim 8, wherein said serine protease of the chymotrypsin superfamily is selected from the group consisting of t-PA, trypsin, trypsin-like protease, chymotrypsin, plasmin, elastase, u-PA, acrosin, activated protein C, Cl esterase, cathepsin G, chymase, kallikrein, thrombin, and Factors VIIa, IXa, Xa, XIa and XIIa.

Claim 10. The gene as claimed in Claim 9, wherein said serine protease is t-PA.

Claim 11. The gene as claimed in Claim 8, wherein said inhibitor is a member selected from the group consisting of the BPTI family, the Kazal family, the SSI family, the serpin family, the soybean trypsin inhibitor (Kunitz) family, the potato inhibitor family, and the Bowman-Birk family.

Claim 12. The gene as claimed in Claim 11, wherein said inhibitor of the serpin family is selected from the group consisting of PAI-1, PAI-2 and PAI-3, Cl esterase inhibitor, alpha-2-antiplasmin, contrapsin, alpha-1-antitrypsin, antithrombin III, protease nexin I, alpha-1-antichymotrypsin, protein C inhibitor, heparin cofactor II and growth hormone regulated protein.

Claim 13. The gene as claimed in Claim 12, wherein said serpin is PAI-1.

Claim 14. The gene as claimed in Claim 8, wherein said gene encodes a mutant selected from the group consisting of t-PA(R₃₀₄->S), t-PA(R₃₀₄->E), t-PA(Del₂₉₆₋₃₀₂), t-PA(R₂₉₈->E), t-PA(R₂₉₉->E) and t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E).

Claim 15. Plasmid pSVT7(RI⁻)/t-PA(R₃₀₄->S).

Claim 16. Plasmid pSVT7(RI⁻)/t-PA(R₃₀₄->E).

Claim 17. Plasmid pSVT7(RI⁻)/t-PA(Del₂₉₆₋₃₀₂).

Claim 18. Plasmid pSVT7(RI⁻)/t-PA(R₂₉₈->E).

Claim 19. Plasmid pSTE/t-PA(R₂₉₉->E).

Claim 20. Plasmid pSTE/t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E).

Claim 21. pSVT7(RI⁻)/t-PA(R₃₀₄->S) [DH-1]
having the identifying characteristics of ATCC No. 67894.

Claim 22. pSVT7(RI⁻)/t-PA(R₃₀₄->E) [DH-1]
having the identifying characteristics of ATCC No. 67896.

Claim 23. pSVT7(RI⁻)/t-PA(Del₂₉₆₋₃₀₂) [DH-1]
having the identifying characteristics of ATCC No. 67895.

Claim 24. pSVT7(RI⁻)/t-PA(R₂₉₈->E) [DH-1]
having the identifying characteristics of ATCC No. 68157.

Claim 25. pSTE/t-PA(R₂₉₉->E) [DH-1]
having the identifying characteristics of ATCC No. 68154.

Claim 26. pSTE/t-PA(K₂₉₆, R₂₉₈, R₂₉₉->E, E, E) [DH-1] having the identifying characteristics of ATCC No. 68153.

Claim 27. A mutant of a serine protease inhibitor which inhibits a mutant of a serine protease of the chymotrypsin superfamily which is resistant to inhibition by its cognate inhibitor.

Claim 28. The mutant as claimed in Claim 27, wherein said serine protease inhibitor is a member selected from the group consisting of the BPTI family, the Kazal family, the SSI family, the Kunitz family, the potato inhibitor family, the Bowman-Birk family and the serpin family.

Claim 29. The mutant as claimed in Claim 27, wherein said serine protease inhibitor is a member of the serpin family.

Claim 30. The mutant as claimed in Claim 29, wherein said inhibitor of the serpin family is selected from the group consisting of PAI-1, PAI-2 and PAI-3, C1 esterase inhibitor, alpha-2-antiplasmin, contrapsin, alpha-1-antitrypsin, antithrombin III, protease nexin I, alpha-1-antichymotrypsin, protein C inhibitor, heparin cofactor II and growth hormone regulated protein.

Claim 31. The mutant as claimed in Claim 30, wherein said inhibitor of the serpin family is PAI-1.

Claim 32. The mutant as claimed in Claim 27, wherein said serine protease of the chymotrypsin superfamily is selected from the group consisting of t-PA, trypsin, trypsin-like protease, chymotrypsin, plasmin, elastase, u-PA, acrosin, activated protein C, C1 esterase, cathepsin G, chymase, kallikrein, thrombin, and Factors VIIa, IXa, Xa, XIa and XIIa.

Claim 33. The mutant as claimed in Claim 32, wherein said serine protease of the chymotrypsin superfamily is t-PA.

Claim 34. The mutant as claimed in Claim 27, wherein said mutant is selected from the group consisting of PAI-1(E₃₅₀->R) and PAI-1(E₃₅₁->R).

Claim 35. A gene encoding a mutant of a serine protease inhibitor which inhibits a mutant of a serine protease of the chymotrypsin superfamily which is resistant to inhibition by its cognate inhibitor.

Claim 36. The gene as claimed in Claim 35, wherein said serine protease inhibitor is a member selected from the group consisting of the BPTI family, the Kazal family, the SSI family, the Kunitz family, the potato inhibitor family, the Bowman-Birk family and the serpin family.

Claim 37. The gene as claimed in Claim 36, wherein said serine protease inhibitor is a member of the serpin family.

Claim 38. The gene as claimed in Claim 37, wherein said inhibitor of the serpin family is selected from the group consisting of PAI-1, PAI-2 and PAI-3, Cl esterase inhibitor, alpha-2-antiplasmin, contrapsin, alpha-1-antitrypsin, antithrombin III, protease nexin I, alpha-1-antichymotrypsin, protein C inhibitor, heparin cofactor II and growth hormone regulated protein.

Claim 39. The gene as claimed in Claim 38, wherein said inhibitor of the serpin family is PAI-1.

Claim 40. The gene as claimed in Claim 35, wherein said serine protease of the chymotrypsin superfamily is selected from the group consisting of t-PA, trypsin, trypsin-like protease, chymotrypsin, plasmin, elastase, u-PA, acrosin, activated protein C, Cl esterase, cathepsin G, chymase, kallikrein, thrombin, and Factors VIIa, IXa, Xa, XIa and XIIa.

Claim 41. The gene as claimed in Claim 40, wherein said serine protease of the chymotrypsin superfamily is t-PA.

Claim 42. The gene as claimed in Claim 35, wherein said gene encodes a mutant selected from the group consisting of PAI-1(E₃₅₀->R) and PAI-1(E₃₅₁->R).

Claim 43. Plasmid pPAIST7HS(E₃₅₀->R).

Claim 44. Plasmid pPAIST7HS(E₃₅₁->R).

Claim 45. pPAIST7HS(E₃₅₀->R) [DH-1] having the identifying characteristics of ATCC No. 68155.

Claim 46. pPAIST7HS(E₃₅₁->R) [DH-1]

having the identifying characteristics of ATCC
No. 68156.

1 / 9

	16		39	50
TRYPSIN	IVGGYTCGAN	TVPYQVSLNSGYH FCGGSLSNSQ
			296 302	
TPA LT.CHAIN	IKGGLFADIA	SHPWQAAIFA	KHRRSPGERF LCGGILISSC
UROKINASE	IGGEFTTIEN	Q.PWFAAIYR	RHRGGS.VTY VCGGSLSMSFC
PLASMIN	VVGGCVAPHP	SWPWQVSLRTRFGMH FCGGTLISFE
PROTEIN C		DQEDQVDPRL	IDGKMTRRGD	S.PWQVLLDSKKKL ACGAVLIHES
THROMBIN	IVEGQDAEVG	LSPWQVMLFRKSPQEL LCGASLISDR
	57			
TRYPSIN		WVVSAAHCYK	S.....GQIV	RLGEDNINVV EG.NEQFISA SKSIVH....
	322			350
TPA LT. CHAIN		WILSAAHCFO	ERFPPHHLTV	ILGR.TYRVV PGESEKFEV EKYIVHK...
UROKINASE		WVISATHCFI	DYPKEDYIV	YLGR.SRLNS NTQEMKFEV ENLILHK...
PLASMIN		WVLTAABCLE	KSPRPSSYKV	ILGA.BOEVN LEPHVQIEIV SRLFL.....
PROTEIN C		WVLTAABCMD	ESKKLL...V	RLGEYDLRW EKWEL.DLDI KEVVFH....
THROMBIN		WVLTAABCLL	YPPWDK...N	FTVDDLVRV GKHSRTRYER KVEKISMLDK
	102			
TRYPSIN	PSYNS	NTLNNDIMLI	KLKSA..... ASLNSRVASI SLPTSCASAG
			371	400
TPA LT. CHAIN	EFDD	DTYDNDIALL	QLKSDSSRCA QESSV.VRTV CLPPADLQLP
UROKINASE	DYSADT	LABHNDIALL	KIRSKGRCA QPSRT.IQTI CLPSMYNDPQ
PLASMIN		EPTRKDIALL	KLSSP..... AVITDKVIPA CLPSPNYVVA
PROTEIN C	PNYSK	STTDNDIALL	HLAQP..... ATLSQTIVPI CLPDSGLAER
THROMBIN		TYIHPRYNWK	ENLDRDIALL	KLKRP..... IELSDYIHPV CLPDKQTAAK
	150			
TRYPSIN	TQCL	ISGWGNTKSS	GT.SYPDVLK CLKAPILSDS SCKSAYPGQ.
TPA LT. CHAIN	DW....	TECE	LSGYGKHEAL	SP.FYSERLK EAHVRLYPSS RCTSOHLLNR
UROKINASE	FG....	TSCE	ITGFGKENST	DY.LYPEOLK MTVVKLISHR ECQOEHYYS
PLASMIN	DR....	TECF	ITGWGETQGT	...FGAGLLK EAQLPVIENT VCNRYEFLNG
PROTEIN C		ELNQAGQETL	VTGWGYHSSR	E.KEAKRNR FVLNFIKIPV VPHNECSEVM
THROMBIN		LLH.AGFKGR	VTGWGNRRET	WTTSAEVQP SVLQVNLPL VERPVCKAST
	195 200			
TRYPSIN	ITSNMFC	AGYL.EGG..	...KDSCQGD SGGPVVCS..GKLQGI
	450			478
TPA LT. CHAIN	T..	VTDNMLC	AGDTRSGGPQ	ANLHDACQGD SGGPLVCLND ..GRMTLVGI
UROKINASE	E..	VTRMLC	AAD.....PQ	.WKTDSCQGD SGGPLVCSLQ ..GRMTLTGI
PLASMIN	R..	VQSTELC	AGHL.....	..ATDSCQGD SGGPLVCFEK ..DKYILQGV
PROTEIN C		SNMVSENMLC	AGIL.....	GDRQDACEGD SGGPMVASFH ..GTWFLVGL
THROMBIN		RIRITDNMFC	AGYK...PGE	GKRGDACEGD SGGPFVMKSP YNNRWYQMGI
	214			245
TRYPSIN		VSWGSGCAQK	NKPGVYTKVC	NYVSWIKQTI ASN.....
	500			527
TPA LT. CHAIN		ISWGLGCGQK	DVPGVYTKVT	NYLDWIRDNM RP.....
UROKINASE		VSWGRCALK	DKPGVYTRVS	HFLPWIRSH KEENGLAL..
PLASMIN		TSWGLGCARP	NKPGVYVRVS	RFVTWIEGVM RNN.....
PROTEIN C		VSWGEGCGLL	HNYGVYTKVS	RYLDWIHGHI RDKEAPQKSW AP
THROMBIN		VSWGEGCDRD	GKYGFYTHVF	RLKKWIKQVI DRLGS.....

2 / 9

PAI-1
Antitrypsin
PAI-2
A-chymotryp
A2-antiplas
A-thrombIII
HeparinCoIIGSKGPLD	QLEKGGETAQ	SADPQWEQLN	NKNLSMPLLP
Clinhhibitor	NPNATSSSSQ	DPESLQDRGE	GKVATTVISR	MLFVEPILEV	SSLPTTNSTT
PAI-1	1
Antitrypsin	VHHFPSY
PAI-2	EDPQGD
A-chymotryp	1
A2-antiplas	NSPLD
A-thrombIII	GNQEPGGQTA
HeparinCoIICHGSPV	DICTAKPRDI	PHNPMCIYRS	PEKKATEDEG
Clinhhibitor	ADPHKENTVT	NDWIPEGEED	DDYLDLEKIF	SEDDDYIDIV	DSLSVSPTDS
PAI-1	VAHLA.....
Antitrypsin	AAQKTDTSHE	DQDHPTFNKI	TPNLAEPAPS	LYRQLAE.QS	KDRNVVFSFY
PAI-2	50
A-chymotrypMEDLCVA	NTLFAFNLPK	HLAK.ASPTQ	NFLSPWSIS
A2-antiplas	EENLTQENOD	RGTHVDLGLA	SANV.DFAPS	LYRQLVL.KA	LDRNVIPSPL
A-thrombIII	LKSPFGVCSR	DFTPEQTHRL	ARAHMAFTAD	LPSLVAQ.TS	TCPNLILSPL
HeparinCoIISEQKIP	EATNRRVWEL	SKANSRPATT	FYQHLADSEN	DNDNIFLSPL
Clinhhibitor	DVSAGNIIQL	FHGKSRIQRL	NILNAKFAFN	LYRVLDQVN	TFDNIFIAPV
PAI-1
Antitrypsin	SIATAFAMLS	LGTRADTHEE	ILEGLNFHLT	E.....
PAI-2	STMANVYNGS	RGSTEDQMAK	VLOFNEVGAN	AVTPMTPENF	TSCGFMQOIQ
A-chymotryp	SISTALAPLS	LGAENTTLTE	ILKASSSPHG	D.....
A2-antiplas	SVALALSHLA	LGAQNTLQK	LOOVLEHAGS	F.....
A-thrombIII	SISTAFAMTK	LGACNDTLQK	LNEVFRPDTI	SEKTSQIHF
HeparinCoII	GISTAMGHIS	LGLKGETHEQ	VHSILHFKDF	VN.....
Clinhhibitor	SIASLLTQVL	LGAGQNTKTN	LESILSYPKD	FTCVHQALKG	F.....
PAI-1	100
Antitrypsin	ISTTDAIPVQ
PAI-2	LTTDGGFLPS
A-chymotryp	KGSYPDAILQ	AQAADKIHSS	FRSLSSAINA	STGDYL.LES	VNKLFGKSA
A2-antiplas	LSMGNAMFVK
A-thrombIII	FRLAARMYLO
HeparinCoII	LVSANRLFGD
Clinhhibitor	LRSVNDLYIQ
PAI-1
Antitrypsin
PAI-2
A-chymotryp
A2-antiplas
A-thrombIII
HeparinCoII
Clinhhibitor
PAI-1
Antitrypsin
PAI-2
A-chymotryp
A2-antiplas
A-thrombIII
HeparinCoII
Clinhhibitor

3 / 9

150
PAI-1 NLLGKGAVDQ LTRLVLVNAL YFNGQWKTPF PDSSTHRLPF HKSDGSTVSV
Antitrypsin DLV..KELDR DTVFALVNYI FFKGKWERPF EVKDTEZEDF HVDQVTTVKV

200
PAI-2 PEGSVDGDTR MVLVNAVYFK GKWKTPFERK LNGLYFFRVN SAQRTPVQMM
A-chymotryp DLI..KDPDS QTMMLVNYI FFKAKWEMPF DPQDTHQSRF YLSKKKWMV
A2-antiplas EFLS..GLPE DTVLLLLNAI HFQGFWRNKF DPSTLQDSSF HLDEQFTVPV
A-thrombIII DVIPSEAINZ LTVLVLVNTI YFRGLWKSFP SPENTRKELF YKADGESCSA
HeparinCoII DALE..NIDP ATOMMILNCI YFRGSWVNKF PVENTHNNHF RLNEREVVKV
Clinhibitor RLDD..SLPS DTRLVLLNAI YLSAKWKTTF DPKKTRMEPF HFKNSVIKVP

200
PAI-1 PMMAQTNRKN YTEFTTPDGH YYDILELPYH GDTLSMFIAA FYEKE..VPL
Antitrypsin PMMKRLGMFN IQHC.KKLSS W..VLLMKYL GNANAIFFLP DEGR.....L


250
PAI-2 YLREKLNIGY IEDLRAQ... ILELPYAGDV SMFLLLPDEI ADVSTGLELL
A-chymotryp PMMSLHHLTI FYFRDEELSC ..TVVELKYT GNABALFILP DQDR.....M
A2-antiplas EMHQARTYPL RWFLLEQPEI ..QVAFPPFK NNHSFVVLPV TH.....FEW
A-thrombIII SHMYQEGKFR YRR..VAEGT ..QVLELPFK GDDITHVLIL PK.....PEK
HeparinCoII SMHQTGNFL AANDQELDCD ...ILQLEYV GGISMLIVVP HKM....SGM
Clinhibitor MMNSKKYPVA BFIDQTLKAK .VGQLQL..S HNLSLVILVP QNLK...HRL

250
PAI-1 SALTNILSAQ LISHWKGHMT ..RLPRLVL PKFSLETEVD LR.KPLENLG
Antitrypsin QHLENELTHD IITKPLENED ..RRSASLHL PKLSITGTVD LK.SVLGQLG

300
PAI-2 ESEITYDKLN KWTSKDKMAE DEVEVYIPQF KLEEHYELR. SILRSMGHED
A-chymotryp EEVEAMLLPE TLKRWDSLE F.REIGELYL PKFSISRADYN LN.DILLQLG
A2-antiplas NVSQVLANLS WDTLHPPLVW ..ERPTKVRP PKLYLKHQMD LV.ATLSQLG
A-thrombIII SLAKVEKELT PEVLQEWLDE LEENMLVVMH PRFRIEDGFS LK.EQLQDMG
HeparinCoII KTLAQLTFR VVERWQKSMT ..NRTREVLL PKFKLEKNYN LV.KSLKLMG
Clinhibitor EDMEQALSFS VFKAIMEKLE MSKFQPTLLT LPRIKVTTSQ DMLSIMKLE

300
PAI-1 HTDMFRQ... FOADFTSLSD QEPLEHVAQAL QKVKEVNES GTVASSST..
Antitrypsin ITKVFSN... .GADLSGVTE EAPLKLKAV HRAVLTIDEK GTEAAGAM..
350
PAI-2 AFNR...GRA NFSGHSERND LPLSEVPHQA MVDVNEEGTE AAAGTGGV..
A-chymotryp IEKAPTS... .KADLSGITG ARNLAVSQV HXVSDVFEV GTEASAAT..
A2-antiplas LQKLFOA... .FDLRGISE Q.SLVVSGVO HOSTLELSEV GVEAAAAT..
A-thrombIII LVDLFSPEKS KLPGIVAEGR D.DLYVSDAF HXAPLEVNEE GSEAAAAT..
HeparinCoII IRLFPD.... .KNGNMAGIS DQRIADLFR HOGTITVNEE GTQATTVT..
Clinhibitor FFDPSYD... .LNLCLGTE DFDLQVSAHQ HQTVELETTET GVEAAAAS..
350
PAI-1 AVIVSARMAP EK....IIND RPFLFVVREN FTGTVLPMGO VMEF.....
Antitrypsin FLEAIPMSIP PE....VKFN KPFVFLMIEQ NTRSPFPMGR VVNPTQK..
PAI-2 ...MTGRTGH GGPQ..FVAD HPFLFLIMHK ITCILFFGR FCSP.....
A-chymotryp AVKITLLSAL VETRTIVRFN RPFLMIIVPT DTQNIFFMSK VTNP.SKPR
A2-antiplas .SIAMSRNSL SS....FSVN RPFLFFIFED TTGLPLFVGS VRNPNPSAPR
A-thrombIII AVVIAGRSLN PNKVT.FKAN RPFLVFIREV PLNTIIFMGR VANPCVK..
HeparinCoII TVGFHPLSTQ VR....FTVD RPFLFLIYEH RTSCLLFMGR VANPSRS..
Clinhibitor .AISVARTLL V.....FEVQ QPFLFVLWDQ QHKFPVPMGR VYDPRA..
PAI-1
Antitrypsin
PAI-2
A-chymotryp CIKQWGSQ..
A2-antiplas ELKEQDQSPG NKDFLOSLKG FFRGDKLFGP DLKLVPMEE DYPQFGSPK
A-thrombIII
HeparinCoII
Clinhibitor

4 / 9



5 / 9




Figure 5

6 / 9





Figure 6

7 / 9



8 / 9





Figure 8

9 / 9



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US90/00947

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC
 IPC(5): C07K 15/00 C12N 1/20, 9/48.76, 15/00 US: 424/94.2, 94.3, 94.63, 94.64; 435/172.3, 212 to 226, 252.33, 320; 530/380, 381, 384, 386, 392, 393, 536/27

II. FIELDS SEARCHED

Classification System	Minimum Documentation Searched ?
US	Classification Symbols 424/94.2, 94.3, 94.63, 94.64; 435/172.3, 212 to 226, 252.33, 320 530/380, 381, 384, 386, 392, 393; 536/27; 935/10, 11, 14, 27

Documentation Searched other than Minimum Documentation
 to the extent that such documents are included in the fields searched *

Automated Patent Search 1975-1990, BIOSIS Data Base 1969-1990; Keywords: T-PA, PAI-1, serine protease, protease inhibitor; u-PA, acrosin, etc.; PAI-2, PAI-3, alpha-2-antiplasmin, etc.

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
A	B. Barrett et al. (eds.), "Proteinase Inhibitors", published 1986 by Elsevier Science Publishers BV (Biomedical Division) (Amsterdam), See pages 403-420.	1-46
A	ANNUAL REVIEW OF BIOCHEMISTRY, Volume 46, issued 1977 (IKRAUT), "Serine Proteases: Structure and Mechanism of Catalysis", See pages 331-358.	1-46
Y	THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 261, No. 22 issued 05 August 1986 (N.R. MATHESON ET AL.) "Recombinant DNA-derived Forms of Human -Proteinase Inhibitor", See pages 10404-10409.	1-46
Y	FEBS. Letters, Volume 157 number 2, issued July 1983, (W. STRABBURGER ET AL.) "Adaptation of plasminogen activator sequences to known protease structures", See pages 219-223.	1-46
Y	BIOCHEMISTRY, Volume 26, issued 1987 (W.E. HOLMES ET AL.) "Characterization of Recombinant Human -Antiplasmin and of Mutants Obtained by Site-Directed Mutagenesis of the Reactive Site", See pages 5153-5140.	1-46

* Special categories of cited documents: **

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

30 MAY 1990

International Searching Authority

ISA/US

Date of Mailing of this International Search Report

25 JUL 1990

Signature of Authorized Officer

LARRY MILLSTEIN

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	BIOCHEMISTRY, Volume 27, issued 1988 (P. J. BRAUN ET AL.)". Use of Site-Directed Mutagenesis to Investigate the Basis for the Specificity of Hirudin", See pages 6517-6522.	1-46
Y	THE JOURNAL OF CLINICAL INVESTIGATION, Volume 80, issued August 1987 (M. SCHAPIRA ET AL.) "Protection by Recombinant -Antitrypsin Ala ³⁵⁷ Arg ³⁵⁸ against Arterial Hypotension Induced by Factor XII Fragment", See pages 582-585.	1-46

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	<u>THE JOURNAL OF CLINICAL INVESTIGATION</u> , Volume 76, issued December 1985, (M. SCHAPIRA ET AL.) Recombinant -Antitrypsin Pittsburgh (Met ³⁵⁸ Arg) Is a Potent Inhibitor of Plasma Kallikrein and Activated Factor XII Fragment" See pages 635-637.	1-46
Y	EP, A. 0,093,619 (D. V. GOEDEL ET AL.) 09 November 1983 (see entire document).	1-46
Y	<u>THE NEW ENGLAND JOURNAL OF MEDICINE</u> , Volume 309, issued 22 September 1983 (M.C. OWEN ET AL.) "Mutation of antitrypsin to antithrombin", See pages 694-698.	1-46